

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K/A**

(Amendment No. 2)

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 20, 2015**

---

**Sucampo Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-33609**

(Commission File Number)

**30-0520478**

(IRS Employer  
Identification No.)

**805 King Farm Boulevard, Suite 550**

**Rockville, MD 20850**

(Address of principal executive offices, including zip code)

**(301) 961-3400**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

On October 20, 2015, the Registrant completed its acquisition of 10,262,903 shares of R-Tech Ueno, a corporation organized under Japanese law (the “Target”) and 318,400 stock acquisition rights of Target pursuant to a tender offer in Japan (the “Tender Offer”) pursuant to which the Registrant’s wholly-owned Japanese subsidiary, Sucampo Pharma LLC (the “Purchaser”), offered to purchase all of the outstanding shares of the Target’s common stock (other than the shares acquired pursuant to the Purchase Agreement (as defined in the next sentence)). In addition, on October 20, 2015, the Registrant acquired 8,571,900 shares of Target pursuant to the terms of the Share Purchase Agreement (“Purchase Agreement”) by and between the Registrant and the founders of the Target, who are also the founders of the Registrant, and a related entity. Following these acquisitions, the Registrant directly and indirectly owned approximately 98% of the outstanding shares of Target. The Registrant acquired the remaining 2% of outstanding shares of R-Tech Ueno through a squeeze-out process under Japanese law on December 8, 2015.

This amendment amends the Current Report on Form 8-K filed on October 22, 2015, as amended on June 28, 2016 (as amended, the “Current Report”), to include a signed audit report in Exhibit 99.1 and updated pro forma condensed combined financial statements in Exhibit 99.2. This amendment does not amend or otherwise affect the other disclosures in the Current Report.

**Item 9.01. Financial Statements and Exhibits.**

(a) *Financial Statements of Business Acquired.* The audited consolidated financial statements of R-Tech Ueno as of March 31, 2015 and 2014 for the fiscal years ended March 31, 2015, 2014 and 2013 are included as Exhibit 99.1 and are incorporated by reference into this Item 9.01(a) and made a part hereof.

(b) *Pro Forma Financial Information.* The following unaudited pro forma financial information related to the acquisition by the Registrant of R-Tech Ueno is attached hereto as Exhibit 99.2 and incorporated by reference into this Item 9.01(b) and made a part hereof.

- (i) Unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2015 and the year ended December 31, 2014
- (ii) Unaudited pro forma condensed combined balance sheet as of September 30, 2015

(c) *Exhibits.*

<u>Exhibit No.</u>	<u>Description</u>
23.1	Consent of Deloitte, R-Tech Ueno’s independent auditors
99.1	Audited Consolidated Financial Statements of R-Tech Ueno
99.2	Pro Forma Condensed Combined Financial Statements

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SUCAMPO PHARMACEUTICALS, INC.**

By: /s/ Andrew Smith  
Andrew Smith  
Chief Financial Officer

Date: July 11, 2016



## EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
23.1	Consent of Deloitte, R-Tech Ueno's independent auditors
99.1	Audited Consolidated Financial Statements of R-Tech Ueno
99.2	Pro Forma Condensed Combined Financial Statements

INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in Registration Statement No. 333-201566 on Form S-3 and Registration Statement No. 333-147420 on Form S-8 of Sucampo Pharmaceuticals, Inc. of our report dated June 24, 2016, related to the financial statements of R Tech Ueno, Ltd. as of March 31, 2015 and 2014 and for each of the three years in the period ended March 31, 2015 (which report expresses an unmodified opinion and includes an emphasis-of-matter paragraph regarding the differences between accounting principles generally accepted in Japan and those generally accepted in the United States of America), appearing in this Current Report on Form 8-K/A of Sucampo Pharmaceuticals, Inc.

/s/ DELOITTE TOUCHE TOHMATSU LLC

Tokyo, Japan

June 24, 2016

***R-Tech Ueno, Ltd.***

*Financial Statements for the Years Ended  
March 31, 2015, 2014 and 2013, and  
Independent Auditors' Report*

---

## **INDEPENDENT AUDITORS' REPORT**

To the Board of Directors and Shareholders of R-Tech Ueno, Ltd.  
Tokyo, Japan:

We have audited the accompanying financial statements of R-Tech Ueno, Ltd. (the "Company"), which comprise the balance sheets as of March 31, 2015 and 2014 and the related statements of income, changes in equity, and cash flows for each of the three years in the period ended March 31, 2015, and the related notes to the financial statements (all expressed in Japanese yen).

### **Management's Responsibility for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in Japan ("Japanese GAAP"); this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditors' Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Opinion**

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of R-Tech Ueno, Ltd. as of March 31, 2015 and 2014 and the results of its operations and its cash flows for each of the three years in the period ended March 31, 2015, in accordance with Japanese GAAP.

---

**Emphasis of Matter**

Japanese GAAP varies in certain significant respects from accounting principles generally accepted in the United States of America. Information relating to the nature and effect of such differences is presented in Note 17 to the financial statements. Our opinion is not modified with respect to this matter.

**Convenience Translation**

Our audits also comprehended the translation of Japanese yen amounts into U.S. dollar amounts and, in our opinion, such translation has been made in conformity with the basis stated in Note 1 to the financial statements. Such U.S. dollar amounts are presented solely for the convenience of readers outside Japan.

/s/ DELOITTE TOUCHE TOHMATSU LLC

Tokyo, Japan  
June 24, 2016

---



**Balance Sheets**  
**March 31, 2015 and 2014**

ASSETS	Thousands of Yen		Thousands of U.S. Dollars (Note 1)
	2015	2014	2015
<b>CURRENT ASSETS:</b>			
Cash and cash equivalents (Note 12)	¥ 4,362,911	¥ 3,215,011	\$ 36,358
Time deposits (Note 12)	3,400,000	3,400,000	28,333
Receivables (Note 13):			
Trade accounts (Note 12)	824,949	415,900	6,875
Other	79,235	127	660
Inventories (Note 4)	1,544,071	1,319,444	12,867
Deferred tax assets (Note 10)	142,418	50,650	1,187
Other current assets (Note 13)	200,150	549,673	1,668
Total current assets	10,553,734	8,950,805	87,948
<b>PROPERTY, PLANT AND EQUIPMENT:</b>			
Buildings and structures	533,006	527,725	4,442
Machinery and equipment	659,077	659,077	5,492
Furniture and fixtures	736,699	730,575	6,139
Lease assets	20,023	20,023	167
Total	1,948,805	1,937,400	16,240
Accumulated depreciation	(1,600,484)	(1,521,628)	(13,337)
Net property, plant and equipment	348,321	415,772	2,903
<b>INVESTMENTS AND OTHER ASSETS:</b>			
Investment securities (Notes 3 and 12)	4,646,846	1,828,767	38,724
Trademarks	3,717	26,017	31
Software	17,413	13,044	145
Security deposits and guarantee deposits (Note 13)	52,360	70,797	436
Other assets	41,166	48,937	343
Total investments and other assets	4,761,502	1,987,562	39,679
<b>TOTAL</b>	<b>¥ 15,663,557</b>	<b>¥ 11,354,139</b>	<b>\$ 130,530</b>
<b>LIABILITIES AND EQUITY</b>			
<b>CURRENT LIABILITIES:</b>			
Payables (Note 12):			
Trade accounts	¥ 360,257	¥ 189,941	\$ 3,002
Lease liabilities (Note 5)	4,948	5,153	41
Other (Note 13)	199,877	220,951	1,666
Income taxes payable (Note 12)	361,669	302,589	3,014
Accrued expenses	18,226	13,564	152
Advance received from customers (Note 13)	119,102	147,429	993
Other current liabilities	91,098	19,299	759
Total current liabilities	1,155,177	898,926	9,627
<b>LONG-TERM LIABILITIES:</b>			
Long-term debt (Notes 5 and 12)	1,049,810	647,954	8,748
Lease liabilities (Note 5)	4,743	9,691	40
Deferred tax liabilities (Note 10)	1,416,290	572,735	11,802
Asset retirement obligations (Note 7)	41,295	40,590	344
Other	29,306	29,306	245
Total long-term liabilities	2,541,444	1,300,276	21,179
<b>COMMITMENTS AND CONTINGENT LIABILITIES</b>			
<b>EQUITY (Notes 8, 9 and 16):</b>			
Common stock - authorized, 38,400,000 shares; issued, 19,311,800 shares in 2015, 19,301,600 shares in 2014 and 19,290,400 shares in 2013	661,760	658,675	5,515
Capital surplus	601,560	598,475	5,013
Stock acquisition rights	73,601	50,801	613
Retained earnings:			
Legal reserve	14,540	14,540	121
Unappropriated	7,506,747	6,690,276	62,556
Treasury stock - at cost, 52 shares in 2015	(82)	-	(1)
Unrealized gain on available-for-sale securities	3,108,810	1,142,170	25,907
Total equity	11,966,936	9,154,937	99,724
<b>TOTAL</b>	<b>¥ 15,663,557</b>	<b>¥ 11,354,139</b>	<b>\$ 130,530</b>

See notes to financial statements.

**Statements of Income**  
**Years Ended March 31, 2015, 2014 and 2013**

	Thousands of Yen			Thousands of U.S. Dollars (Note 1)
	2015	2014	2013	2015
NET SALES (Note 13)	¥ 6,559,429	¥ 5,578,322	¥ 4,540,011	\$ 54,662
COST OF SALES	2,286,181	2,026,644	1,703,348	19,052
Gross profit	4,273,248	3,551,678	2,836,663	35,610
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (Note 11)	2,663,760	2,172,710	2,064,522	22,198
Operating income	1,609,488	1,378,968	772,141	13,412
OTHER INCOME (EXPENSES):				
Interest and dividend income	2,505	2,610	5,493	21
Loss on disposal of property, plant and equipment	(87)	(106)	(4,668)	(1)
Foreign exchange gain	143,158	52,524	93,236	1,193
Other - net	8,029	2,756	6,701	67
Other income - net	153,605	57,784	100,762	1,280
INCOME BEFORE INCOME TAXES	1,763,093	1,436,752	872,903	14,692
INCOME TAXES (Note 10):				
Current	563,734	386,412	350,493	4,697
Deferred	(99,652)	16,004	(30,322)	(830)
Total income taxes	464,082	402,416	320,171	3,867
NET INCOME	¥ 1,299,011	¥ 1,034,336	¥ 552,732	\$ 10,825
		Yen		U.S. Dollars
	2015	2014	2013	2015
PER SHARE OF COMMON STOCK (Note 14):				
Basic net income	¥ 67.3	¥ 53.6	¥ 28.3	\$ 0.6
Diluted net income	66.8	53.2	28.1	0.6
Cash dividends applicable to the year	30.0	25.0	15.0	0.3

See notes to financial statements.

R-Tech Ueno, Ltd.

Statements of Changes in Equity  
Years Ended March 31, 2015, 2014 and 2013

	Thousands			Thousands of Yen					
	Outstanding Number of Shares of Common Stock	Common Stock	Capital Surplus	Stock Acquisition Rights	Retained Earnings		Treasury Stock	Unrealized Gain on Available-for-Sale Securities	Total Equity
					Legal Reserve	Unappropriated			
BALANCE, MARCH 31, 2012	19,588,800	¥ 653,987	¥ 593,787	¥ 12,434	¥ 14,540	¥ 5,875,959	¥ -	¥ 944,386	¥ 8,095,093
Net income						552,732			552,732
Cash dividends, ¥15 per share						(295,332)			(295,332)
Purchase of treasury stock	(400,000)						(188,062)		(188,062)
Retirement of treasury stock						(188,063)	188,062		(1)
Exercise of stock options	1,600	264	264						528
Net change in the year				12,768				4,436	17,204
BALANCE, MARCH 31, 2013	19,290,400	654,251	594,051	25,202	14,540	5,945,296	-	948,822	8,182,162
Net income						1,034,336			1,034,336
Cash dividends, ¥15 per share						(289,356)			(289,356)
Exercise of stock options	11,200	4,424	4,424						8,848
Net change in the year				25,599				193,348	218,947
BALANCE, MARCH 31, 2014	19,301,600	658,675	598,475	50,801	14,540	6,690,276	-	1,142,170	9,154,937
Net income						1,299,011			1,299,011
Cash dividends, ¥25 per share						(482,540)			(482,540)
Purchase of treasury stock							(82)		(82)
Exercise of stock options	10,200	3,085	3,085						6,170
Net change in the year				22,800				1,966,640	1,989,440
BALANCE, MARCH 31, 2015	19,311,800	¥ 661,760	¥ 601,560	¥ 73,601	¥ 14,540	¥ 7,506,747	¥ (82)	¥ 3,108,810	¥ 11,966,936

	Thousands of U.S. Dollars (Note 1)								
	Common Stock	Capital Surplus	Stock Acquisition Rights	Retained Earnings		Treasury Stock	Unrealized Gain on Available-for-Sale Securities	Total Equity	
				Legal Reserve	Unappropriated				
BALANCE, MARCH 31, 2014	\$ 5,489	\$ 4,987	\$ 423	\$ 121	\$ 55,752	\$ -	\$ 9,518	\$ 76,290	
Net income					10,825			10,825	
Cash dividends, \$0.2 per share					(4,021)			(4,021)	
Purchase of treasury stock						(1)		(1)	
Exercise of stock options	26	26						52	
Net change in the year			190				16,389	16,579	
BALANCE, MARCH 31, 2015	\$ 5,515	\$ 5,013	\$ 613	\$ 121	\$ 62,556	\$ (1)	\$ 25,907	\$ 99,724	

See notes to financial statements.

The numbers of shares and dividends have been retrospectively restated for the share split conducted as of July 1, 2013 (at a ratio of 1:200).



**Statements of Cash Flows**  
**Years Ended March 31, 2015, 2014 and 2013**

	Thousands of Yen			Thousands of U.S. Dollars (Note 1)
	2015	2014	2013	2015
<b>OPERATING ACTIVITIES:</b>				
Income before income taxes	¥ 1,763,093	¥ 1,436,752	¥ 872,903	\$ 14,692
Adjustments for:				
Income taxes - paid	(514,389)	(184,882)	(407,359)	(4,287)
Depreciation and amortization	121,296	137,835	129,804	1,011
Share based compensation	34,787	28,016	13,296	290
Foreign exchange gain	(121,994)	(60,746)	(81,224)	(1,017)
Litigation settlement (Note 13)	(30,000)	-	-	(250)
Changes in assets and liabilities, net of effects:				
(Increase) decrease in trade accounts receivable	(409,049)	741,902	(688,606)	(3,409)
(Increase) decrease in inventories	(224,627)	(37,059)	13,695	(1,872)
(Increase) decrease in interest and dividends receivable	(137)	1,478	(1,488)	(1)
(Increase) decrease in prepaid expenses	(5,739)	(1,140)	4,776	(48)
(Increase) decrease in advance payments	350,123	(327,873)	76,256	2,918
Increase (decrease) in trade accounts payable	170,316	(62,502)	128,433	1,419
Increase (decrease) in other accounts payable	26,620	(158,951)	154,716	222
Increase (decrease) in accrued expenses	4,662	(6,715)	2,074	39
(Decrease) increase in advance received	(28,326)	(50,480)	105,921	(236)
Other - net	2,066	(27,455)	(55,815)	18
Total adjustments	(624,391)	(8,572)	(605,521)	(5,203)
Net cash provided by operating activities	1,138,702	1,428,180	267,382	9,489
<b>INVESTING ACTIVITIES:</b>				
Payment into time deposits	(6,800,000)	(3,400,000)	(4,600,000)	(56,667)
Withdrawal of time deposits	6,800,000	3,400,000	4,600,000	56,667
Purchases of property, plant and equipment	(18,605)	(105,010)	(72,332)	(155)
Purchases of intangible assets	(9,627)	(4,510)	(68,111)	(80)
Payments for security deposits and guarantee deposits	(1,833)	-	-	(16)
Other - net	1	1,902	(57,129)	0
Net cash used in investing activities	(30,064)	(107,618)	(197,572)	(251)
<b>FINANCING ACTIVITIES:</b>				
Repayment of lease liabilities	(4,758)	(4,880)	(4,006)	(40)
Proceeds from issuance of long-term debt	401,856	401,093	246,861	3,349
Repurchase of treasury stock	(82)	-	(188,064)	(1)
Dividends paid	(482,385)	(288,626)	(294,953)	(4,019)
Exercise of stock options	2,638	6,430	0	22
Net cash (used in) provided by financing activities	(82,731)	114,017	(240,162)	(689)
<b>FOREIGN CURRENCY TRANSLATION ADJUSTMENTS ON CASH AND CASH EQUIVALENTS</b>				
	121,993	60,746	80,369	1,017
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>1,147,900</b>	<b>1,495,325</b>	<b>(89,983)</b>	<b>9,566</b>
<b>CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</b>	<b>3,215,011</b>	<b>1,719,686</b>	<b>1,809,669</b>	<b>26,792</b>
<b>CASH AND CASH EQUIVALENTS, END OF YEAR</b>	<b>¥ 4,362,911</b>	<b>¥ 3,215,011</b>	<b>¥ 1,719,686</b>	<b>\$ 36,358</b>

See notes to financial statements.

**Notes to Financial Statements**  
**Years Ended March 31, 2015, 2014 and 2013**

---

**1. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS**

The accompanying financial statements have been prepared in accordance with the provisions set forth in the Japanese Financial Instruments and Exchange Act and its related accounting regulations and in accordance with accounting principles generally accepted in Japan ("Japanese GAAP"), which are different in certain respects from accounting principles generally accepted in the United States of America ("U.S. GAAP") as to the application and disclosure requirements. A discussion of certain significant differences between Japanese GAAP and U.S. GAAP is presented under Note 17 of these financial statements.

In preparing these financial statements, certain reclassifications and rearrangements have been made to the financial statements issued domestically in order to present them in a form which is more familiar to readers outside Japan. In addition, certain reclassifications have been made to the financial statements for the years ended March 31, 2014 and 2013 to conform to the classifications used in 2015.

The financial statements are stated in Japanese yen, the currency of the country in which R-Tech Ueno, Ltd. (the "Company") is incorporated and operates. The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan and have been made at the rate of ¥120.00 to \$1, the approximate rate of exchange at March 31, 2015. Such translations should not be construed as representations that the Japanese yen amounts could be converted into U.S. dollars at that or any other rate.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**a. Cash Equivalents** - Cash equivalents are short-term investments that are readily convertible into cash and that are exposed to insignificant risk of changes in value.

Cash equivalents include time deposits, which mature or become due within three months of the date of acquisition.

**b. Inventories** - Inventories are stated at the lower of cost, determined by the average cost method for finished products, work in process and raw material, and by the actual cost method for supplies, or net selling value.

**c. Investment Securities** - Investment securities are classified and accounted for, depending on management's intent, as available-for-sale securities and reported at fair value, with unrealized gains and losses, net of applicable taxes, reported in a separate component of equity.

**d. Property, Plant and Equipment** - Property, plant and equipment are stated at cost. Depreciation of property, plant and equipment of the Company is computed by the declining-balance method except for buildings which are depreciated using the straight-line method, based on the estimated useful lives of the assets.

The estimated useful lives are as follows:

Buildings:	5 to 34 years
Structures:	4 to 15 years
Machinery and equipment:	2 to 8 years
Furniture and fixtures:	2 to 15 years

- e. **Intangible Assets** - Intangible assets with estimated useful lives are amortized over their estimated useful lives using the straight-line method.

The estimated useful lives are as follows:

Trademark	10 years
Software	5 years

- f. **Long-Lived Assets** - The Company reviews its long-lived assets for impairment whenever events or changes in circumstance indicate the carrying amount of an asset or asset group may not be recoverable. An impairment loss is recognized if the carrying amount of an asset or asset group exceeds the sum of the undiscounted future cash flows expected to result from the continued use and eventual disposition of the asset or asset group. The impairment loss would be measured as the amount by which the carrying amount of the asset exceeds its recoverable amount, which is the higher of the discounted cash flows from the continued use and eventual disposition of the asset or the net selling price at disposition.

No impairment loss was recorded for the years ended March 31, 2015, 2014 and 2013.

- g. **Pension Plan** - The Company participates in a defined contribution pension plan. Contributions to the pension plan are recorded as expenses when incurred because the plan assets attributable to each participant cannot be reasonably determined.
- h. **Asset Retirement Obligations** - In March 2008, the Accounting Standard Board of Japan ("ASBJ") issued ASBJ Statement No. 18, "Accounting Standard for Asset Retirement Obligations" and ASBJ Guidance No. 21, "Guidance on Accounting Standard for Asset Retirement Obligations." Under this accounting standard, an asset retirement obligation is defined as a legal obligation imposed either by law or contract that results from the acquisition, construction, development and normal operation of a tangible fixed asset and is associated with the retirement of such tangible fixed asset. The asset retirement obligation is recognized as the sum of the discounted cash flows required for the future asset retirement and is recorded in the period in which the obligation is incurred if a reasonable estimate can be made. If a reasonable estimate of the asset retirement obligation cannot be made in the period the asset retirement obligation is incurred, the liability should be recognized when a reasonable estimate of the asset retirement obligation can be made. Upon initial recognition of a liability for an asset retirement obligation, an asset retirement cost is capitalized by increasing the carrying amount of the related fixed asset by the amount of the liability. The asset retirement cost is subsequently allocated to expense through depreciation over the remaining useful life of the asset. Over time, the liability is accreted to its present value each period. Any subsequent revisions to the timing or the amount of the original estimate of undiscounted cash flows are reflected as an adjustment to the carrying amount of the liability and the capitalized amount of the related asset retirement cost.
- i. **Stock Options** - In December 2005, the ASBJ issued ASBJ Statement No. 8, "Accounting Standard for Stock Options" and related guidance. The new standard and guidance are applicable to stock options newly granted on and after May 1, 2006. This standard requires companies to measure the cost of employee stock options based on the fair value at the date of grant and recognize compensation expense over the vesting period as consideration for receiving goods or services. The standard also requires companies to account for stock options granted to non-employees based on the fair value of either the stock options or the goods or services received. In the balance sheet, stock options are presented as stock acquisition rights as a separate component of equity until exercised. The standard covers equity-settled, share-based payment transactions, but does not cover cash-settled, share-based payment transactions. In addition, the standard allows unlisted companies to measure options at their intrinsic value if they cannot reliably estimate fair value.

- j. Research and Development Costs** - Research and development costs are charged to income as incurred.
- k. Leases** - The accounting standard for lease transactions requires that all finance lease transactions be capitalized recognizing lease assets and lease obligations in the balance sheet.

The Company leases certain furniture, which is capitalized and included in lease assets in the balance sheet. Depreciation of leased assets is computed by the straight-line method over the leasing period with no residual value.

- l. Income Taxes** - The provision for income taxes is computed based on the pretax income included in the statement of income. The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Deferred taxes are measured by applying currently enacted income tax rates to the temporary differences.
- m. Foreign Currency Transactions** - All short-term and long-term monetary receivables and payables denominated in foreign currencies are translated into Japanese yen at the exchange rates at the balance sheet date. The foreign exchange gains and losses from translation are recognized in the statement of income.
- n. Per Share Information** - Basic net income per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding for the period, retroactively adjusted for stock splits.

Diluted net income per share reflects the potential dilution that could occur if securities were exercised or converted into common stock. Diluted net income per share of common stock assumes full conversion of the outstanding warrants at the beginning of the year (or at the time of issuance) with an applicable adjustment for related interest expense, net of tax, and full exercise of outstanding warrants.

Cash dividends per share presented in the accompanying statement of income are dividends applicable to the respective fiscal years, including dividends to be paid after the end of the year, retroactively adjusted for stock splits.

- o. Consumption Taxes** - Consumption taxes have been excluded from sales.
- p. Accounting Changes and Error Corrections** - In December 2009, the ASBJ issued ASBJ Statement No. 24, "Accounting Standard for Accounting Changes and Error Corrections" and ASBJ Guidance No. 24, "Guidance on Accounting Standard for Accounting Changes and Error Corrections." Accounting treatments under this standard and guidance are as follows: (1) Changes in Accounting Policies - When a new accounting policy is applied following revision of an accounting standard, the new policy is applied retrospectively unless the revised accounting standard includes specific transitional provisions, in which case the entity shall comply with the specific transitional provisions. (2) Changes in Presentation - When the presentation of financial statements is changed, prior-period financial statements are reclassified in accordance with the new presentation. (3) Changes in Accounting Estimates - A change in an accounting estimate is accounted for in the period of the change if the change affects that period only, and is accounted for prospectively if the change affects both the period of the change and future periods. (4) Corrections of Prior-Period Errors - When an error in prior-period financial statements is discovered, those statements are restated.



### 3. INVESTMENT SECURITIES

Investment securities as of March 31, 2015 and 2014, consisted of the following:

	Thousands of Yen		Thousands of U.S. Dollars
	2015	2014	2015
<b>Non-current:</b>			
Marketable equity securities	¥ 4,646,846	¥ 1,828,767	\$ 38,724
<b>Total</b>	<b>¥ 4,646,846</b>	<b>¥ 1,828,767</b>	<b>\$ 38,724</b>

The costs and aggregate fair values of investment securities at March 31, 2015 and 2014, were as follows:

<u>March 31, 2015</u>	Thousands of Yen			Fair Value
	Cost	Unrealized Gains	Unrealized Losses	
<b>Securities classified as:</b>				
Available-for-sale:				
Equity securities	¥ 55,486	¥ 4,591,360	¥ -	¥ 4,646,846

<u>March 31, 2014</u>	Thousands of Yen			Fair Value
	Cost	Unrealized Gains	Unrealized Losses	
<b>Securities classified as:</b>				
Available-for-sale:				
Equity securities	¥ 55,486	¥ 1,773,281	¥ -	¥ 1,828,767

<u>March 31, 2015</u>	Thousands of U.S. Dollars			Fair Value
	Cost	Unrealized Gains	Unrealized Losses	
<b>Securities classified as:</b>				
Available-for-sale:				
Equity securities	\$ 463	\$ 38,261	\$ -	\$ 38,724

No impairment losses on available-for-sale equity securities were recorded for the years ended March 31, 2015, 2014 and 2013.

### 4. INVENTORIES

Inventories at March 31, 2015 and 2014, consisted of the following:

	Thousands of Yen		Thousands of U.S. Dollars
	2015	2014	2015
Finished products	¥ 138,275	¥ 127,800	\$ 1,152
Work in process	1,160,809	1,126,444	9,673
Raw materials and supplies	244,987	65,200	2,042
<b>Total</b>	<b>¥ 1,544,071</b>	<b>¥ 1,319,444</b>	<b>\$ 12,867</b>

## 5. LONG-TERM DEBT

Long-term debt as of March 31, 2015 and 2014 is summarized below.

	Thousands of Yen		Thousands of
	2015	2014	U.S. Dollars
Unsecured non-interest-bearing loans from Japan Science and Technology Agency (JST)	¥ 1,049,810	¥ 647,954	\$ 8,748
Obligations under finance leases	9,691	14,844	81
Total	1,059,501	662,798	8,829
Less current portion	(4,948)	(5,153)	(41)
Long-term debt, less current portion	¥ 1,054,553	¥ 657,645	\$ 8,788

There is no long-term debt with a maturity date within five years. The maturity of long-term debt from JST will be determined for ten years from the launch of a product which is the outcome of related research and development activity.

## 6. PENSION PLAN

The Company participates in a defined contribution pension plan, and records the required contributions as retirement benefit expenses. The amount of retirement benefit expenses for the years ended March 31, 2015, 2014 and 2013 were ¥21,584 thousand (\$180 thousand), ¥20,802 thousand and ¥21,818 thousand, respectively.

## 7. ASSET RETIREMENT OBLIGATIONS

### a. Overview of the Asset Retirement Obligations

Asset retirement obligations relate to restoration requirements associated with the real estate lease agreements for the Tokyo head office, Sanda plant and Kobe Research Center.

### b. Method of Calculating the Amount of Asset Retirement Obligations

The amount of asset retirement obligations was calculated by applying a usage period estimated to range between 13 and 27 years from lease inception date, and the discount rate was derived from the average yield of government bonds with terms corresponding to the usage period, which range from 1.146% to 2.266%.

### c. Changes in Asset Retirement Obligations

The changes in asset retirement obligations for the years ended March 31, 2015 and 2014, were as follows:

	Thousands of Yen		Thousands of
	2015	2014	U.S. Dollars
Balance at beginning of year	¥ 40,590	¥ 30,130	\$ 338
Additional provisions associated with the inception of lease assets	-	9,658	-
Reconciliation associated with passage of time	705	802	6
Balance at end of year	¥ 41,295	¥ 40,590	\$ 344

## 8. EQUITY

Japanese companies are subject to the Companies Act of Japan (the "Companies Act"). The significant provisions in the Companies Act that affect financial and accounting matters are summarized below:

### **a. Dividends**

Under the Companies Act, companies can pay dividends at any time during the fiscal year in addition to the year-end dividend upon resolution at the shareholders' meeting. For companies that meet certain criteria including (1) having a Board of Directors, (2) having independent auditors, (3) having an Audit & Supervisory Board, and (4) the term of service of the directors being prescribed as one year rather than the normal two-year term by its articles of incorporation, the Board of Directors may declare dividends (except for dividends-in-kind) at any time during the fiscal year if the Company has prescribed so in its articles of incorporation. The Company meets all the above criteria.

Semiannual interim dividends may also be paid once a year upon resolution by the Board of Directors if the articles of incorporation of the Company so stipulate. The Companies Act provides certain limitations on the amounts available for dividends or the purchase of treasury stock. The limitation is defined as the amount available for distribution to the shareholders, but the amount of net assets after dividends must be maintained at no less than ¥3,000 thousand.

### **b. Increases/Decreases and Transfer of Common Stock, Reserve and Surplus**

The Companies Act requires that an amount equal to 10% of dividends must be appropriated as a legal reserve (a component of retained earnings) or as additional paid-in capital (a component of capital surplus), depending on the equity account charged upon the payment of such dividends, until the aggregate amount of legal reserve and additional paid-in capital equals 25% of the common stock. Under the Companies Act, the total amount of additional paid-in capital and legal reserve may be reversed without limitation. The Companies Act also provides that common stock, legal reserve, additional paid-in capital, other capital surplus and retained earnings can be transferred among the accounts within equity under certain conditions upon resolution of the shareholders.

### **c. Treasury Stock and Treasury Stock Acquisition Rights**

The Companies Act also provides for companies to purchase treasury stock and dispose of such treasury stock by resolution of the Board of Directors. The amount of treasury stock purchased cannot exceed the amount available for distribution to the shareholders which is determined by a specific formula. Under the Companies Act, stock acquisition rights are presented as a separate component of equity. The Companies Act also provides that companies can purchase both treasury stock acquisition rights and treasury stock. Such treasury stock acquisition rights are presented as a separate component of equity or deducted directly from stock acquisition rights.

On July 1, 2013, the Company made a two hundred-for-one stock split by way of a free share distribution based on the resolution of the Board of Directors' meeting held on May 15, 2013. The numbers of shares, earnings per share and dividends per share presented in the financial statements have been retrospectively restated for the share split.

## 9. STOCK OPTIONS

### a. Expenses for Stock Options and Account Titles

	Thousands of Yen			Thousands of
	2015	2014	2013	U.S. Dollars
Share based compensation recorded as selling, general and administrative expenses	¥ 34,787	¥ 26,599	¥ 12,897	\$ 290

### b. Amount Recorded as Other Income Due to Forfeiture of Unexercised Stock Options

	Thousands of Yen			Thousands of
	2015	2014	2013	U.S. Dollars
Other income	¥ 8,453	¥ -	¥ -	\$ 70

### c. Stock Options Outstanding as of March 31, 2015

Stock Option	Persons Granted	Number of Shares*	Date of Grant	Exercise Price	Exercise Period
2006 Stock Option (1)	2 directors 4 employees	329,600 shares	2/20/2006	¥1,475 (\$12.3)	From 2/17/2008 to 2/16/2016
2006 Stock Option (2)	3 directors 2 employees	53,600 shares	7/1/2006	¥1,475 (\$12.3)	From 6/29/2008 to 6/28/2016
2011 Stock Option (1)	2 directors	40,000 shares	8/10/2011	¥1 (\$0.0)	From 8/11/2011 to 8/10/2041
2011 Stock Option (2)	9 employees	10,000 shares	8/10/2011	¥1 (\$0.0)	From 8/11/2011 to 8/10/2016
2012 Stock Option (1)	2 directors	40,000 shares	8/10/2012	¥1 (\$0.0)	From 8/11/2012 to 8/10/2042
2012 Stock Option (2)	17 employees	19,000 shares	8/10/2012	¥1 (\$0.0)	From 8/11/2012 to 8/10/2017
2013 Stock Option (1)	2 directors	9,900 shares	8/9/2013	¥1 (\$0.0)	From 8/10/2013 to 8/9/2043
2013 Stock Option (2)	12 employees	8,800 shares	8/9/2013	¥1 (\$0.0)	From 8/10/2013 to 8/9/2018
2014 Stock Option (1)	2 directors	14,000 shares	8/14/2014	¥1 (\$0.0)	From 8/15/2014 to 8/14/2044
2014 Stock Option (2)	13 employees	15,400 shares	8/14/2014	¥1 (\$0.0)	From 8/15/2014 to 8/14/2019

\* The numbers of shares indicated above are calculated based on the number of shares after the share split was conducted as of July 1, 2013 (at a ratio of 1:200).

The details of stock options are as follows:

Stock Option	Vesting Conditions	Service Period
2006 Stock Option (1)	Each holder shall hold the position of director, corporate auditor or employee of the Company at the time of exercising the stock option as well as its grant date. However, those who have retired from the position of director or corporate auditor due to expiry of the service term or employees who have lost their position for reasons other than for cause may exercise their stock options after the Company's IPO and within one month from the retirement date.	Not applicable
2006 Stock Option (2)	Same as the above 2006 Stock Option (1)	Not applicable
2011 Stock Option (1)	A person who was granted stock options may basically exercise the stock options only within 10 days following the date of retirement as the Company's director. In addition, each stock option may not be exercised in part.	Not applicable
2011 Stock Option (2)	A person who was granted stock options is required to hold the position of director, corporate auditor, or employee of the Company at the time of exercise. However, those who retired from their office due to expiry of the service term or were separated from the Company for reasons other than for cause may exercise their stock options within 30 days from the separation date. In addition, each stock option may not be exercised in part.	Not applicable
2012 Stock Option (1)	Same as the above 2011 Stock Option (1)	Not applicable
2012 Stock Option (2)	Same as the above 2011 Stock Option (2)	Not applicable
2013 Stock Option (1)	Same as the above 2011 Stock Option (1)	Not applicable
2013 Stock Option (2)	Same as the above 2011 Stock Option (2)	Not applicable
2014 Stock Option (1)	Same as the above 2011 Stock Option (1)	Not applicable
2014 Stock Option (2)	Same as the above 2011 Stock Option (2)	Not applicable

**d. Stock Option Activity**

The numbers of options indicated below have been retrospectively restated for the share split conducted as of July 1, 2013 (at a ratio of 1:200).

	2006 Stock Option (1)	2006 Stock Option (2)	2011 Stock Option (1)	2011 Stock Option (2)	2012 Stock Option (1)	2012 Stock Option (2)	2013 Stock Option (1)	2013 Stock Option (2)	2014 Stock Option (1)	2014 Stock Option (2)
	(Shares)									
<b>Year Ended March 31, 2014</b>										
<b>Non-vested</b>										
April 1, 2013 - Outstanding	-	-	-	5,400	-	15,800	-	-	-	-
Granted	-	-	-	-	-	-	9,900	8,800	-	-
Canceled	-	-	-	-	-	-	-	-	-	-
Vested	-	-	-	5,400	-	5,600	9,900	1,000	-	-
March 31, 2014 - Outstanding	-	-	-	-	-	10,200	-	7,800	-	-
<b>Vested</b>										
April 1, 2013 - Outstanding	165,200	4,800	40,000	3,800	40,000	2,400	-	-	-	-
Vested	-	-	-	5,400	-	5,600	9,900	1,000	-	-
Exercised	4,000	-	-	3,200	-	3,000	-	200	-	-
Canceled	-	-	-	-	-	-	-	-	-	-
March 31, 2014 - Outstanding	161,200	4,800	40,000	6,000	40,000	5,000	9,900	800	-	-
<b>Year Ended March 31, 2015</b>										
<b>Non-vested</b>										
April 1, 2014 - Outstanding	-	-	-	-	-	10,200	-	7,800	-	-
Granted	-	-	-	-	-	-	-	-	14,000	15,400
Canceled	-	-	-	-	-	1,200	-	1,600	-	1,500
Vested	-	-	-	-	-	9,000	-	3,000	14,000	3,400
March 31, 2015 - Outstanding	-	-	-	-	-	-	-	3,200	-	10,500
<b>Vested</b>										
April 1, 2014 - Outstanding	161,200	4,800	40,000	6,000	40,000	5,000	9,900	800	-	-
Vested	-	-	-	-	-	9,000	-	3,000	14,000	3,400
Exercised	-	-	-	400	-	4,600	-	800	-	400
Canceled	-	-	-	2,200	-	1,000	-	800	-	500
March 31, 2015 - Outstanding	161,200	4,800	40,000	3,400	40,000	8,400	9,900	2,200	14,000	2,500
Exercise price	¥1,475 (\$12.3)	¥1,475 (\$12.3)	¥1 (\$0.0)	¥1 (\$0.0)	¥1 (\$0.0)	¥1 (\$0.0)	¥1 (\$0.0)	¥1 (\$0.0)	¥1 (\$0.0)	¥1 (\$0.0)
Average stock price at exercise	¥- (\$-)	¥- (\$-)	¥- (\$-)	¥1,499 (\$12.5)	¥- (\$-)	¥1,459 (\$12.2)	¥- (\$-)	¥1,499 (\$12.5)	¥- (\$-)	¥1,499 (\$12.5)
Fair value price at grant date	¥- (\$-)	¥- (\$-)	¥259 (\$2.2)	¥354 (\$2.9)	¥223 (\$1.9)	¥305 (\$2.5)	¥1,736 (\$14.5)	¥1,827 (\$15.2)	¥1,188 (\$9.9)	¥1,308 (\$10.9)

**e. Assumptions Used to Measure the Fair Value of the 2015 Stock Option**

**i. 2006 Stock Option (1) and 2006 Stock Option (2)**

When these stock options were granted, the Company was not listed on the public markets. Therefore, the Company estimates the fair value of these stock options based on their intrinsic value which is calculated using the DCF method.

ii. *Stock Options granted after 2011*

Estimate method: Black-Scholes option pricing model

	2011 Stock Option (1)	2011 Stock Option (2)	2012 Stock Option (1)	2012 Stock Option (2)	2013 Stock Option (1)	2013 Stock Option (2)	2014 Stock Option (1)	2014 Stock Option (2)
Volatility of stock price *1	85.0%	85.0%	75.6%	51.9%	86.7%	76.3%	82.0%	74.4%
Estimated remaining outstanding period (Years) *2	12.0	3.5	10.9	3.5	9.9	3.5	8.9	3.5
Estimated dividend per share *3	15	15	15	15	15	15	25	25
Risk free interest rate *4	1.3%	0.2%	0.9%	0.1%	0.8%	0.2%	0.4%	0.1%

Note

\*1 Periods for computation using actual price:

2011 Stock Option (1) and 2011 Stock Option (2)	- 3 years (from April 2008 to August 2011),
2012 Stock Option (1)	- 4 years (from April 2008 to August 2012),
2012 Stock Option (2)	- 3 years (from February 2009 to August 2012),
2013 Stock Option (1)	- 5 years (from April 2008 to August 2013),
2013 Stock Option (2)	- 3 years (from February 2010 to August 2013),
2014 Stock Option (1)	- 6 years (from April 2008 to August 2014),
2014 Stock Option (2)	- 3 years (from February 2011 to August 2014)

\*2 Estimated remaining outstanding period is determined based on the estimated remaining period to the retirement of persons granted or the assumption that all the options are exercised by the medium date of exercise period.

\*3 Estimated dividend per share is calculated using the actual dividends in each year.

\*4 For the risk free rate, the Company uses the yield of Japanese Treasury bonds applicable to the estimated remaining outstanding period of the options.

iii. *Estimation of the number of stock options vested*

Because it is difficult to reasonably estimate the number of options that will be forfeited in the future, only the number of actual forfeited options is reflected.

iv. *Intrinsic value*

(i) No stock options are measured at intrinsic value as of March 31, 2015. The total intrinsic value of stock options measured at intrinsic value is ¥6,756 thousand as of March 31, 2014.

(ii) The total amount of intrinsic value of exercised stock options as of the exercise date was ¥2,055 thousand (\$17 thousand) and ¥470 thousand for the years ended March 31, 2015 and 2014, respectively.

## 10. INCOME TAXES

The Company is subject to Japanese national and local income taxes which, in the aggregate, resulted in normal effective statutory tax rates of approximately 35.6%, 38.0% and 38.0% for the years ended March 31, 2015, 2014 and 2013, respectively.

The tax effects of significant temporary differences which resulted in deferred tax assets and liabilities at March 31, 2015 and 2014, are as follows:

	Thousands of Yen		Thousands of
	<u>2015</u>	<u>2014</u>	<u>U.S. Dollars</u>
<b>Deferred tax assets:</b>			
Research and development costs	¥ 135,171	¥ 48,816	\$ 1,126
Enterprise tax payable	31,018	28,222	258
Accrued expenses	1,665	18,928	14
Asset retirement obligations	13,334	14,445	111
Long-term non trade payables	9,463	10,430	79
Other	26,413	21,808	221
Less valuation allowance	-	(23,651)	-
<b>Total</b>	<b>¥ 217,064</b>	<b>¥ 118,998</b>	<b>\$ 1,809</b>
<b>Deferred tax liabilities:</b>			
Unrealized gain on available-for-sale securities	¥ 1,482,550	¥ 631,110	\$ 12,354
Other	8,386	9,973	70
<b>Total</b>	<b>1,490,936</b>	<b>641,083</b>	<b>12,424</b>
<b>Net deferred tax liabilities</b>	<b>¥ 1,273,872</b>	<b>¥ 522,085</b>	<b>\$ 10,615</b>

A reconciliation between the normal effective statutory tax rates and the actual effective tax rates reflected in the accompanying statement of income for the year ended March 31, 2015, with the corresponding figures for 2014 and 2013, is as follows:

	<u>2015</u>	<u>2014</u>	<u>2013</u>
Normal effective statutory tax rate	35.6%	38.0%	38.0%
Tax deduction on research and development costs	(10.9)	(10.3)	(8.6)
Tax on accumulated earnings	1.7	-	-
Effect of reduction of income tax rates on net deferred tax assets	1.2	-	-
Valuation allowance	(1.3)	0.5	0.4
Income taxes for prior year	-	-	6.4
Other - net	0.0	(0.2)	0.5
<b>Actual effective tax rate</b>	<b>26.3%</b>	<b>28.0%</b>	<b>36.7%</b>

New tax reform laws enacted in 2015 in Japan changed the normal effective statutory tax rate for the fiscal year beginning on or after April 1, 2015, to approximately 33.0% and for the fiscal year beginning on or after April 1, 2016, to approximately 32.3%. The effect of these changes was to decrease deferred tax liabilities, net of deferred tax assets, by ¥131,109 thousand (\$1,093 thousand) and increase unrealized gain on available-for-sale securities by ¥151,515 thousand (\$1,263 thousand) in the balance sheet as of March 31, 2015, and to increase income taxes-deferred in the statement of income for the year then ended by ¥20,406 thousand (\$170 thousand).



## 11. RESEARCH AND DEVELOPMENT COSTS

Research and development costs charged to income were ¥1,830,027 thousand (\$15,250 thousand), ¥1,372,578 thousand and ¥1,279,566 thousand for the years ended March 31, 2015, 2014 and 2013, respectively.

## 12. FINANCIAL INSTRUMENTS AND RELATED DISCLOSURES

### a. Company Policy for Financial Instruments

The Company limits its fund management to short-term deposits, and does not have loans from banks or other financial institutions. However, the Company received non-interest-bearing loans from the JST for development of medicine for retinitis pigmentosa. In addition, the Company does not have any derivatives.

### b. Nature and Extent of Risks Arising from and Risk Management for Financial Instruments

Trade receivables are exposed to customer credit risk and the Company mitigates such risk in accordance with its credit management policies. In addition, trade receivables from product sales are denominated in foreign currencies and exposed to the market risk of fluctuation in foreign currency exchange rates. The Company reduces such risks by setting policies for foreign currency-denominated financial assets.

All investment securities are common shares of Sucampo Pharmaceuticals Inc., and the Company monitors their market value on a quarterly basis.

All trade payables and other payables are due within one year.

### c. Concentration of Credit Risk

The ratio of receivables from major customers among trade receivables for the years ended March 31, 2015 and 2014 is as follows:

<u>Name of Customers</u>	<u>2015</u>	<u>2014</u>
Santen Pharmaceutical Co., Ltd.	21.0%	18.4%
Takeda Pharmaceutical Company Limited	41.9%	37.5%
Sucampo AG	36.1%	43.1%

d. *Fair Values of Financial Instruments*

Fair values of financial instruments are based on quoted prices in active markets. If a quoted price is not available, another rational valuation technique is used instead.

i. *Fair value of financial instruments*

	Thousands of Yen		
	Carrying Amount	Fair Value	Unrealized Gain/Loss
<u>March 31, 2015</u>			
Cash and cash equivalents	¥ 4,362,911	¥ 4,362,911	¥ -
Time deposits	3,400,000	3,400,000	-
Trade receivables	824,949	824,949	-
Investment securities	4,646,846	4,646,846	-
<b>Total</b>	<b>¥ 13,234,706</b>	<b>¥ 13,234,706</b>	<b>¥ -</b>
Trade payables	¥ 360,257	¥ 360,257	¥ -
Other payables	199,877	199,877	-
Income taxes payable	361,669	361,669	-
<b>Total</b>	<b>¥ 921,803</b>	<b>¥ 921,803</b>	<b>¥ -</b>
<u>March 31, 2014</u>			
Cash and cash equivalents	¥ 3,215,011	¥ 3,215,011	¥ -
Time deposits	3,400,000	3,400,000	-
Trade receivables	415,900	415,900	-
Investment securities	1,828,767	1,828,767	-
<b>Total</b>	<b>¥ 8,859,678</b>	<b>¥ 8,859,678</b>	<b>¥ -</b>
Trade payables	¥ 189,941	¥ 189,941	¥ -
Other payables	220,951	220,951	-
Income taxes payable	302,589	302,589	-
<b>Total</b>	<b>¥ 713,481</b>	<b>¥ 713,481</b>	<b>¥ -</b>
	Thousands of U.S. Dollars		
	Carrying Amount	Fair Value	Unrealized Gain/Loss
<u>March 31, 2015</u>			
Cash and cash equivalents	\$ 36,358	\$ 36,358	\$ -
Time deposits	28,333	28,333	-
Trade receivables	6,875	6,875	-
Investment securities	38,724	38,724	-
<b>Total</b>	<b>\$ 110,290</b>	<b>\$ 110,290</b>	<b>\$ -</b>
Trade payables	\$ 3,002	\$ 3,002	\$ -
Other payables	1,666	1,666	-
Income taxes payable	3,014	3,014	-
<b>Total</b>	<b>\$ 7,682</b>	<b>\$ 7,682</b>	<b>\$ -</b>

### Cash and Cash Equivalents and Time Deposits

The carrying values of cash and cash equivalents and time deposits approximate fair value because of their short maturities.

### Investment Securities

The fair values of investment securities are measured at the quoted market price of the stock exchange for the equity instruments. Fair value information for investment securities by classification is included in Note 3.

### Trade Receivables, Trade Payables, Other Payables and Income Taxes Payables

The fair values of these receivables and payables approximate fair value because of their short maturities.

- ii. *Carrying amount of financial instruments whose fair value cannot be reliably determined*

	Thousands of Yen		Thousands of U.S. Dollars
	2015	2014	2015
Long term debt	¥ 1,049,810	¥ 647,954	\$ 8,748

Long-term debt consists of borrowings from JST whose fair value cannot reliably determined because its repayment date has not been determined. The maturity of long-term debt from JST will be determined for ten years from the launch of a product which is the outcome of related research and development activity.

### **e. Maturity Analysis for Financial Assets and Securities with Contractual Maturities**

	Thousands of Yen			
	Due in One Year or Less	Due after One Year through Five Years	Due after Five Years through Ten Years	Due after Ten Years
<u>March 31, 2015</u>				
Cash and cash equivalents	¥ 4,362,911	¥ -	¥ -	¥ -
Time deposits	3,400,000	-	-	-
Trade receivables	824,949	-	-	-
Total	¥ 8,587,860	¥ -	¥ -	¥ -

	Thousands of Yen			
	Due in One Year or Less	Due after One Year through Five Years	Due after Five Years through Ten Years	Due after Ten Years
<u>March 31, 2014</u>				
Cash and cash equivalents	¥ 3,215,011	¥ -	¥ -	¥ -
Time deposits	3,400,000	-	-	-
Trade receivables	415,900	-	-	-
Total	¥ 7,030,911	¥ -	¥ -	¥ -

	Thousands of U.S. Dollars			
	Due in One Year or Less	Due after One Year through Five Years	Due after Five Years through Ten Years	Due after Ten Years
<u>March 31, 2015</u>				
Cash and cash equivalents	\$ 36,358	\$ -	\$ -	\$ -
Time deposits	28,333	-	-	-
Trade receivables	6,875	-	-	-
<b>Total</b>	<b>\$ 71,566</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>

### 13. RELATED PARTY TRANSACTIONS

The related party transactions of the Company for the years ended March 31, 2015, 2014 and 2013 are as follows:

	Thousands of Yen			Thousands of U.S. Dollars
	<u>2015</u>	<u>2014</u>	<u>2013</u>	<u>2015</u>
CRO arrangement with Sucampo Pharma Americas, Inc. (Note A)	¥ 66,212	¥ 59,115	¥ 74,006	\$ 552
CRO arrangement with Sucampo Pharma, LLC (Note A)	19,354	44,224	13,197	161
CRO arrangement with Sucampo AG (Note A)	7,451	32,261	61,112	62
Sales of products to Sucampo AG (Note B)	1,529,096	913,841	671,209	12,742
Lease of land to Sucampo Pharma, LLC (Note C)	0	0	4,634	0
License granted to Sucampo AG (Note D)	0	0	45,570	0
License granted by Sucampo AG (Note E)	0	0	59,570	0
Lease of land and buildings from Ueno Fine Chemicals Industry, LTD. (Note F)	4,812	4,812	67,288	40
Settlement payment to Ueno Fine Chemicals Industry, LTD. (Note G)	30,000	0	0	250

Note:

- A. These Contract Research Organization (CRO) arrangements primarily consists of several R&D services related to medical drug products provided to Sucampo Pharma Americas, Inc., Sucampo Pharma, LLC and Sucampo AG, which are subsidiaries of a third party whose majority of shares are owned by the majority shareholders of the Company. The Company provided several R&D support services mainly to research medical drug products, summarize the results, and report to the customers. The terms of the transactions were determined in the same manner as third party transactions.

- B. Sales of products to Sucampo AG include sales of Rescula® (ophthalmic solution) and AMITIZA® (capsule), and their selling prices are determined by taking market prices into consideration. The terms of the transactions are determined in the same way as a third party transaction.
- C. On October 1, 2010, the Company entered into a lease agreement and leased facilities located in the Sanda factory to Sucampo Pharma, LLC. The rental payments were determined by taking real estate appraisal value into consideration.
- D. On April 23, 2009, the Company entered into a licensing agreement whereby the Company granted to Sucampo AG the exclusive rights to develop, manufacture, commercialize, and sell Unoprostone in North America and Canada, for all indications including glaucoma and ocular hypertension. The licensing agreement included contingent payments for reaching various milestones including launching the product within North America and Canada along with certain sales milestones. During the year ended March 31, 2013, Sucampo AG launched the product and paid the Company ¥45,570 thousand, which the Company recognized as revenue. The royalty for this license was determined based on negotiations and by considering market prices.
- E. On February 23, 2009, the Company entered into a licensing agreement whereby the Company was granted by Sucampo AG the exclusive rights to manufacture and market Amitiza in Japan and the Asia-Oceania region. The Company made a payment to Sucampo AG when New Drug Application for Amitiza was approved and beginning of commercialization launch in Japan. The royalty was determined based on negotiations and by considering market prices.
- F. On April 1, 2004, the Company entered into a lease agreement for land and buildings for the Sanda factory and paid rental fees to Ueno Fine Chemicals Industry, LTD., which is a company whose majority of shares are owned by the majority shareholders of the Company and their close family members. The rental fees for the land and buildings were determined by taking real estate appraisal amounts into consideration.
- G. On December 24, 2014, the Company settled a legal dispute with Ueno Fine Chemicals Industry, LTD. regarding the termination of the facilities subject to the lease agreement described in Note F above. In connection with the settlement, the Company paid Ueno Fine Chemicals Industry, LTD. ¥30,000 thousand.

The balance due to or due from related parties at March 31, 2015 and 2014 is as follows:

	Thousands of Yen		Thousands of
	2015	2014	U.S. Dollars
<b>Sucampo Pharma Americas, Inc.:</b>			
Trade receivable	¥ 7,163	¥ 278	\$ 60
Advance received from customers	-	31,881	-
<b>Sucampo Pharma, LLC:</b>			
Trade receivable	¥ -	¥ 1,771	\$ -
Advance received from customers	7,037	6,392	59
<b>Sucampo AG:</b>			
Trade receivable	¥ 297,850	¥ 179,094	\$ 2,482
Other current assets	90,915	75,032	758
<b>Ueno Fine Chemicals Industry, LTD.:</b>			
Security deposits and guarantee deposits	¥ 802	¥ 21,072	\$ 7
Other current assets	401	401	3
Other payables	1,232	4,363	10

#### 14. NET INCOME PER SHARE

Reconciliation of the differences between basic and diluted net income per share ("EPS") for the years ended March 31, 2015, 2014 and 2013, is as follows:

	Thousands	Thousands	Yen	U.S.
	of Yen	of Shares		Dollars
	Net Income	Weighted-Average Shares	EPS	
<b><u>Year Ended March 31, 2015</u></b>				
Basic EPS - Net income available to common shareholders	¥ 1,299,011	19,308	¥ 67.3	\$ 0.6
Effect of dilutive securities:				
Warrants	-	137		
Diluted EPS - Net income for computation	¥ 1,299,011	19,445	¥ 66.8	\$ 0.6
<b><u>Year Ended March 31, 2014</u></b>				
Basic EPS - Net income available to common shareholders	¥ 1,034,336	19,295	¥ 53.6	
Effect of dilutive securities:				
Warrants	-	137		
Diluted EPS - Net income for computation	¥ 1,034,336	19,432	¥ 53.2	
<b><u>Year Ended March 31, 2013</u></b>				
Basic EPS - Net income available to common shareholders	¥ 552,732	19,557	¥ 28.3	
Effect of dilutive securities:				
Warrants	-	84		
Diluted EPS - Net income for computation	¥ 552,732	19,641	¥ 28.1	

15. SEGMENT INFORMATION

a. Description of Reportable Segments

The disclosures of reportable segments are omitted since the Company falls within a single segment of the manufacturing and sale of pharmaceutical products.

b. Information about Products and Services

	Thousands of Yen			
	2015			
	Rescula® Ophthalmic Solution	AMITIZA® Capsule	Research and Development Support Services of Pharmaceuticals	Total
Sales to external customers	¥ 1,291,879	¥ 5,171,116	¥ 96,434	¥ 6,559,429

	Thousands of Yen			
	2014			
	Rescula® Ophthalmic Solution	AMITIZA® Capsule	Research and Development Support Services of Pharmaceuticals	Total
Sales to external customers	¥ 1,483,934	¥ 3,955,601	¥ 138,787	¥ 5,578,322

	Thousands of Yen			
	2013			
	Rescula® Ophthalmic Solution	AMITIZA® Capsule	Research and Development Support Services of Pharmaceuticals	Total
Sales to external customers	¥ 1,811,865	¥ 2,579,829	¥ 148,317	¥ 4,540,011

	Thousands of U.S. Dollars			
	2015			
	Rescula® Ophthalmic Solution	AMITIZA® Capsule	Research and Development Support Services of Pharmaceuticals	Total
Sales to external customers	\$ 10,766	\$ 43,093	\$ 803	\$ 54,662

c. Information about Geographical Areas

i. Sales

	Thousands of Yen				
	2015				
	Japan	U.S.A.	Europe	Other	Total
¥	2,840,669	¥ 3,677,643	¥ 38,789	¥ 2,328	¥ 6,559,429

Thousands of Yen						
2014						
Japan	U.S.A.	Europe	Other	Total		
¥ 2,235,527	¥ 3,307,041	¥ 32,261	¥ 3,493	¥ 5,578,322		

Thousands of Yen						
2013						
Japan	U.S.A.	Europe	Other	Total		
¥ 1,607,648	¥ 2,866,427	¥ 61,112	¥ 4,824	¥ 4,540,011		

Thousands of U.S. Dollars						
2015						
Japan	U.S.A.	Europe	Other	Total		
\$ 23,672	\$ 30,647	\$ 323	\$ 20	\$ 54,662		

Note: Sales are classified by country or region based on the location of customers.

ii. *Property, plant and equipment*

Since the amount of property, plant and equipment located in Japan exceeds 90% of the amount of property, plant and equipment on the balance sheet, descriptions regarding the property, plant and equipment are omitted.

d. *Information about Major Customers*

Name of Customers	Thousands of Yen			Related Products and Services
	Sales			
	2015	2014	2013	
Santen Pharmaceutical Co., Ltd.	¥ 1,289,551	¥ 1,378,951	¥ 1,342,356	Rescula® ophthalmic solution
Takeda Pharmaceutical Company Limited	3,610,682	3,146,436	2,327,735	AMITIZA® capsule
Sucampo AG	1,536,547	946,102	777,892	Rescula® ophthalmic solution, AMITIZA® capsule, research and development support services of pharmaceuticals

Name of Customers	Thousands of U.S. Dollars		Related Products and Services
	Sales		
	2015		
Santen Pharmaceutical Co., Ltd.	\$	10,746	Rescula® ophthalmic solution
Takeda Pharmaceutical Company Limited		30,089	AMITIZA® capsule
Sucampo AG		12,805	Rescula® ophthalmic solution, AMITIZA® capsule, research and development support services of pharmaceuticals



## 16. SUBSEQUENT EVENTS

On May 6, 2015, Sucampo AG and the Company executed a transfer and termination agreement to effectuate the return of all licenses for Unoprostone to the Company. These licenses had provided Sucampo AG with exclusive development and commercialization rights to Unoprostone globally except for Japan, the People's Republic of China, Taiwan and Korea. As a result of this transfer and termination agreement, the Company paid \309,437 thousand (\$2,600 thousand) to Sucampo AG, which included \238,000 thousand (\$2,000 thousand) for the transfer and assignment of certain rights and assets and \71,437 thousand (\$600 thousand) for the reimbursement of an FDA fee.

On June 23, 2015, a stock option plan for remuneration of directors was approved by the Board of Directors of the Company. In addition, a stock option plan for selected employees was approved by the Board of Directors and at the shareholders' meeting on the same date. These stock option plans provide options to purchase a maximum of 36,000 shares of the Company's common stock. The exercise price of these stock options is \1 (\$0.0). The exercise period is from July 8, 2015 to July 8, 2045 for directors and from June 24, 2015 to June 23, 2020 for employees.

## 17. SIGNIFICANT DIFFERENCES BETWEEN JAPANESE GAAP AND U.S. GAAP

Japanese GAAP differs in certain respects from U.S. GAAP. The significant differences between Japanese GAAP and U.S. GAAP as they pertain to the Company are described below, which also includes reconciliations of net income and equity under Japanese GAAP to net income and equity under U.S. GAAP.

### Net Income Reconciliation

	Note	Thousands of Yen		Thousands of
		2015	2014	U.S. Dollars
Net income under Japanese GAAP		¥ 1,299,011	¥ 1,034,336	\$ 10,825
U.S. GAAP adjustments:				
Depreciation of property, plant and equipment	(a)	(25,863)	(15,783)	(215)
R&D revenue	(b)	(23,753)	299	(198)
Advance payment for R&D	(c)	40,971	(45,536)	341
Accrued vacation	(d)	1,378	(2,506)	11
Expired stock options	(e)	(8,453)	-	(70)
Trademark	(f)	22,300	22,300	186
Royalty revenue	(g)	88,557	88,557	738
Subtotal		95,137	47,331	793
Tax effect of adjustments		(53,639)	(22,000)	(447)
Effect of tax rate change on unrealized gain on available-for-sale securities	(h)	151,515	-	1,262
Valuation allowance on deferred tax assets	(i)	(23,651)	6,344	(197)
Net income under U.S. GAAP		¥ 1,468,373	¥ 1,066,010	\$ 12,236

	Yen		U.S. Dollars
	2015	2014	2015
<b>Earnings per share - Basic:</b>			
Under Japanese GAAP	¥ 67.3	¥ 53.6	\$ 0.6
U.S. GAAP adjustments	8.8	1.6	0.1
<b>Under U.S. GAAP</b>	<b>¥ 76.1</b>	<b>¥ 55.2</b>	<b>\$ 0.7</b>
<b>Earnings per share - Diluted:</b>			
Under Japanese GAAP	¥ 66.8	¥ 53.2	\$ 0.6
U.S. GAAP adjustments	8.7	1.7	0.1
<b>Under U.S. GAAP</b>	<b>¥ 75.5</b>	<b>¥ 54.9</b>	<b>\$ 0.7</b>

### Statements of Comprehensive Income

Under Japanese GAAP, the Company is not required to disclose statements of comprehensive income. The statements of comprehensive income under U.S. GAAP are as follows:

	Thousands of Yen		Thousands of U.S. Dollars
	2015	2014	2015
Net income	¥ 1,468,373	¥ 1,066,010	\$ 12,236
Unrealized gain on available-for-sale securities	1,815,125	193,348	15,126
Total other comprehensive income	1,815,125	193,348	15,126
<b>Comprehensive income</b>	<b>¥ 3,283,498</b>	<b>¥ 1,259,358</b>	<b>\$ 27,362</b>

### Equity Reconciliation

	Note	Thousands of Yen		Thousands of U.S. Dollars
		2015	2014	2015
Equity under Japanese GAAP		¥ 11,966,936	¥ 9,154,937	\$ 99,724
U.S. GAAP adjustments:				
Depreciation of property, plant and equipment	(a)	39,724	65,151	331
Inventory	(a)	4,027	4,463	34
R&D revenue	(b)	(5,730)	18,023	(48)
Advance payment for R&D	(c)	(98,138)	(139,109)	(818)
Accrued vacation	(d)	(46,953)	(48,331)	(391)
Expired stock options	(e)	-	-	-
Trademark	(f)	283	(22,017)	2
Royalty revenue	(g)	(453,893)	(542,450)	(3,782)
Subtotal		(560,680)	(664,270)	(4,672)
Tax effect of adjustments		179,315	236,500	1,494
Valuation allowance on deferred tax assets	(i)	-	23,651	-
<b>Equity under U.S. GAAP</b>		<b>¥ 11,585,571</b>	<b>¥ 8,750,818</b>	<b>\$ 96,546</b>

## Cash Flows Reconciliation

There are no significant differences between Japanese GAAP and U.S. GAAP for purposes of presenting or reconciling the statements of cash flows for the years ended March 31, 2015 and 2014.

Notes:

### (a) Depreciation of property, plant and equipment

Under Japanese GAAP, the Company depreciates property, plant and equipment over the estimated useful life of each asset under the declining-balance method, except for buildings, which are depreciated using the straight-line method, and lease assets, which are depreciated using the straight-line method based on the terms of the lease.

Based on FASB ASC 360, "Property, Plant and Equipment," the cost of a productive facility is one of the costs of the services it renders during its useful economic life. U.S. GAAP requires that this cost be recognized over the expected useful life of the facility in such a way as to allocate it as equitably as possible to the periods during which services are obtained from the use of the facility. Accordingly, the Company applied the straight-line method to all property, plant and equipment for U.S. GAAP purposes.

This difference results in an adjustment to accumulated depreciation, inventory and cost of sales.

The total U.S. GAAP adjustments for depreciation expense are allocated to cost of sales and sales, general and administrative expenses, as follows:

	Thousands of Yen		Thousands of U.S. Dollars
	<u>2015</u>	<u>2014</u>	<u>2015</u>
Cost of sales	¥ (11,580)	¥ (12,229)	\$ (96)
Sales, general and administrative expenses	(14,283)	(3,554)	(119)
	<u>¥ (25,863)</u>	<u>¥ (15,783)</u>	<u>\$ (215)</u>

The following table presents a reconciliation of property, plant and equipment from Japanese GAAP to U.S. GAAP as of March 31, 2015 and 2014:

	Thousands of Yen				Thousands of U.S. Dollars	
	2015		2014		2015	
	Gross Carrying Amount	Accumulated Depreciation	Gross Carrying Amount	Accumulated Depreciation	Gross Carrying Amount	Accumulated Depreciation
Balance under Japanese GAAP	¥ 1,948,805	¥ (1,600,484)	¥ 1,937,400	¥ (1,521,628)	\$ 16,240	\$ (13,337)
U.S. GAAP adjustment:						
Change in accumulated depreciation	-	39,724	-	65,151	-	331
Balance under U.S. GAAP	<u>¥ 1,948,805</u>	<u>¥ (1,560,760)</u>	<u>¥ 1,937,400</u>	<u>¥ (1,456,477)</u>	<u>\$ 16,240</u>	<u>\$ (13,006)</u>

### (b) R&D (Research and Development) revenue

Under U.S. GAAP, revenue from Contract Research Organization (CRO) services shall be recognized on a straight-line basis over the contract period. Under Japanese GAAP, the revenue from CRO service is recognized when the final report is submitted to a customer.

### (c) Advance payment for R&D activities

Under U.S. GAAP, advance payment for R&D activities shall be recognized as an expense as the related services are performed. Under Japanese GAAP, advance payment is recognized as an expense when the final report of R&D service is delivered.

(d) Accrued vacation

Under U.S. GAAP, an employer shall accrue a liability for employees' compensation for future absences, such as vacations, if certain conditions are met. Such liabilities are accrued in the periods in which the benefits are earned. Under Japanese GAAP, there is no specific accounting standard for compensated absence, and as a result, liabilities and the corresponding expenses are generally not recognized in Japan.

The total U.S. GAAP adjustments for accrued vacation are allocated to cost of sales and sales, general and administrative expenses, as follows:

	Thousands of Yen		Thousands of
	2015	2014	U.S. Dollars
Cost of sales	¥ (21)	¥ (768)	\$ (0)
Sales, general and administrative expenses	1,399	(1,738)	11
	<u>¥ 1,378</u>	<u>¥ (2,506)</u>	<u>\$ 11</u>

(e) Expired stock options

Under U.S. GAAP, previously recognized compensation cost shall not be reversed if an employee share option, for which the requisite service has been rendered, expires unexercised. Under Japanese GAAP, the Company reverses the amount of previously recognized compensation cost for the expired stock options.

(f) Trademark

The Company acquired the trademark for Rescula from Sucampo AG on June 1, 2005. Under Japanese GAAP, the Company recorded the trademark on the balance sheet at the transaction price, which the Company amortized over 10 years. As of June 1, 2005, the Company and Sucampo AG were under common control. U.S. GAAP requires the Company to record such transaction under common control at the carrying amount for Rescula in the accounts of Sucampo AG at the time the Company purchased the trademark.

(g) Royalty revenue

Under Japanese GAAP, the Company recognized royalty revenue for licensing agreements at the time of receipt of the non-refundable payments including upfront and milestone payments both from Sucampo Pharma Americas, Inc. and Sucampo AG. Under U.S. GAAP, the non-refundable upfront and milestone payments shall be recognized, on a straight-line basis, over the contract period and the remaining contract period after the respective milestones are achieved, respectively.

(h) Effect of tax rate change on unrealized gain on available-for-sale securities

Under U.S. GAAP, when the effective income tax rate changes, the impact of the tax rate change on unrealized gain (loss) on available-for-securities is recognized in income as income taxes expense, whereas under Japanese GAAP, such impact is recognized within equity.

(i) Valuation allowance on deferred tax assets

Under Japanese GAAP, there is prescriptive guidance for considering the realizability of deferred tax assets. Particularly, if an entity's taxable income does not sufficiently exceed the total of deductible temporary differences for each of the most recent years, no deferred tax assets can be recognized for deductible temporary differences whose timing of reversal cannot be reasonably expected.

In accordance with this accounting guidance, the Company recognized a valuation allowance for deferred tax assets relating to certain temporary differences before the year ended March 31, 2015, considering its taxable income level, although the Company had been profitable for many years. However, the valuation allowance was reversed for the year ended March 31, 2015, since the Company's taxable income sufficiently exceeded the total of deductible temporary differences.

Under U.S. GAAP, realizability of deferred tax assets is judgmentally determined based on weighing positive and negative consideration factors in accordance with ASC 740, "Income Tax." As a result of the consideration of such positive and negative factors, the Company does not recognize a valuation allowance on deferred tax assets under U.S. GAAP as of March 31, 2015 and 2014.

\* \* \* \* \*

## UNAUDITED PRO FORMA COMBINED CONSOLIDATED FINANCIAL INFORMATION

The following unaudited pro forma combined consolidated financial information is presented to illustrate the estimated effects of the acquisition of R-Tech Ueno, Ltd. ("R-Tech") by Sucampo Pharmaceuticals, Inc. ("Sucampo") and certain other adjustments listed below, which are collectively referred to as the acquisition adjustments. On August 26, 2015, Sucampo entered into a share purchase agreement with Drs. Ryuji Ueno and Sachiko Kuno and S&R Technology Holdings, LLC, to acquire 44% of outstanding R-Tech shares. The purchase price for these shares was 1,400 Japanese Yen (JPY) per share. Concurrently, Sucampo made an all-cash tender offer in Japan to acquire the remaining 56% of the outstanding shares and stock acquisition rights of R-Tech for 1,900 JPY per share. On October 20, 2015, the transactions contemplated by the share purchase agreement were completed, and the tender offer was concluded. As a result of these transactions, Sucampo acquired approximately 98% of the outstanding shares of R-Tech. Sucampo acquired the remaining 2% of outstanding shares of R-Tech through a squeeze-out process under Japanese law on December 8, 2015 at a price of 1,900 JPY per share. The following pro forma combined consolidated financial information gives effect to the acquisition of 100% of the outstanding shares of R-Tech.

The unaudited pro forma combined consolidated balance sheet as of September 30, 2015 and the unaudited pro forma combined consolidated statements of operations for the nine months ended September 30, 2015 and the year ended December 31, 2014, respectively, are presented herein. The unaudited pro forma combined consolidated balance sheet combines the unaudited balance sheets of Sucampo and R-Tech as of September 30, 2015 and gives effect to the proposed business combination as if it occurred on September 30, 2015. R-Tech's assets and liabilities have been measured at fair value as of October 20, 2015, which represents the date R-Tech was acquired by Sucampo. The purchase price has been allocated as of October 20, 2015 since this information was incorporated in Sucampo's fiscal year 2015 Annual Report filed on Form 10-K and more accurately reflects the fair value of R-Tech's assets acquired and liabilities assumed.

The unaudited pro forma combined consolidated statements of operations combine the historical results of Sucampo and R-Tech for the nine months ended September 30, 2015 and the year ended December 31, 2014 and give effect to the proposed business combination as if it occurred on January 1, 2014. The historical financial information has been adjusted to give effect to pro forma adjustments that are (i) directly attributable to the proposed business combination, (ii) factually supportable, and (iii) with respect to the unaudited combined consolidated statements of operations, expected to have a continuing impact on the combined entity's results.

The unaudited pro forma combined consolidated financial information primarily gives effect to the following adjustments:

- Adjustments to reconcile R-Tech's historical audited and unaudited financial statements prepared in accordance with Japanese GAAP to U.S. GAAP and to convert these statements from Japanese yen to U.S. dollars;
- Application of the acquisition method of accounting in connection with the business combination to reflect total purchase consideration of \$275.1 million;
- Adjustments to reflect financing arrangements entered into in connection with the business combination;
- Reclassification of line items on R-Tech's financial statements to conform to Sucampo's presentation;
- Elimination of intercompany transactions between Sucampo and R-Tech; and
- Transaction costs in connection with the business combination.

The unaudited pro forma combined consolidated statements of operations also include certain other purchase accounting adjustments, including items expected to have a continuing impact on the combined results, such as increased amortization expense on acquired intangible assets. The unaudited pro forma combined consolidated statements of operations do not include the impact of any revenue, cost or other operating synergies that may result from the business combination or any related restructuring costs.

The unaudited pro forma combined consolidated financial information presented is based on the assumptions and adjustments described in the accompanying notes. The unaudited pro forma combined consolidated financial information is presented for illustrative purposes and does not purport to represent what the financial position or results of operations would actually have been if the business combination occurred as of the dates indicated or what the financial position or results would be for any future periods.

---

The unaudited pro forma combined consolidated financial information is derived from the historical financial statements of Sucampo and R-Tech, and should be read in conjunction with (1) the accompanying notes to the unaudited pro forma combined consolidated financial information, (2) the unaudited financial statements as of September 30, 2015 and for the nine months ended September 30, 2015 and notes thereto of Sucampo included in Sucampo's Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2015, which was filed with the SEC on November 4, 2015, (3) the audited financial statements for the fiscal year ended December 31, 2014 and notes thereto of Sucampo included in Sucampo's Annual Report on Form 10-K, which was filed with the SEC on March 9, 2015, and (4) the audited financial statements for the fiscal years ended March 31, 2014 and 2015 and notes thereto of R-Tech, which are included as an exhibit to the Amendment to Sucampo's Current Report on Form 8-K, to which this unaudited pro forma combined consolidated financial information has also been filed as an exhibit (the "Form 8-K/A").

SUCAMPO PHARMACEUTICALS, INC  
 UNAUDITED PRO FORMA COMBINED CONSOLIDATED STATEMENT OF OPERATIONS  
 YEAR ENDED DECEMBER 31, 2014  
 (in thousands)

	Historical		Intercompany Eliminations	Transaction Adjustments	Pro Forma Combined Consolidated
	Twelve Months Ended				
	December 31, 2014	December 31, 2014			
	Sucampo	R-Tech Ueno (see Note 2)	(see Note 3)	(see Note 6)	
<b>Revenues:</b>					
Research and development revenue	\$ 7,246	\$ 567	\$ (567)	\$ -	\$ 7,246
Product royalty revenue	62,775	-	-	-	62,775
Product sales revenue	33,252	52,374	(15,776)	-	69,850
Co-promotion revenue	3,360	-	-	-	3,360
Contract and collaboration revenue	8,817	-	-	-	8,817
<b>Total revenues</b>	<b>115,450</b>	<b>52,941</b>	<b>(16,343)</b>	<b>-</b>	<b>152,048</b>
<b>Costs and expenses:</b>					
Costs of goods sold	16,269	19,201	(15,776)	-	19,694
Intangible assets impairment	5,631	-	-	-	5,631
Intangible assets amortization	-	-	-	22,775	22,775
Research and development expenses	20,566	16,125	(567)	-	36,124
General and administrative expenses	31,230	5,503	-	-	36,733
Selling and marketing expenses	14,523	1,787	-	-	16,310
<b>Total costs and expenses</b>	<b>88,219</b>	<b>42,616</b>	<b>(16,343)</b>	<b>22,775</b>	<b>137,267</b>
<b>Income from operations</b>	<b>27,231</b>	<b>10,325</b>	<b>-</b>	<b>(22,775)</b>	<b>14,781</b>
<b>Non-operating income (expense):</b>					
Interest income	172	23	-	-	195
Interest expense	(1,520)	-	-	(23,479)	(24,999)
Other non-operating income (expense), net	1,250	1,124	-	-	2,374
<b>Total other income</b>	<b>(98)</b>	<b>1,147</b>	<b>-</b>	<b>(23,479)</b>	<b>(22,430)</b>
<b>Income (loss) before income taxes</b>	<b>27,133</b>	<b>11,472</b>	<b>-</b>	<b>(46,254)</b>	<b>(7,649)</b>
Income tax provision	(14,005)	(2,309)	-	16,739	425
<b>Net income (loss)</b>	<b>\$ 13,128</b>	<b>\$ 9,163</b>	<b>\$ -</b>	<b>\$ (29,515)</b>	<b>\$ (7,224)</b>

See accompanying Notes to unaudited pro forma combined consolidated financial information.



**SUCAMPO PHARMACEUTICALS, INC.**  
**UNAUDITED PRO FORMA COMBINED CONSOLIDATED STATEMENT OF OPERATIONS**  
**NINE MONTHS ENDED SEPTEMBER 30, 2015**  
(in thousands)

	Historical		Intercompany Eliminations (see Note 3)	Transaction Adjustments (see Note 6)	Pro Forma Combined Consolidated
	Nine Months Ended				
	September 30, 2015	September 30, 2015			
	Sucampo	R-Tech Ueno (see Note 2)			
Revenues:					
Research and development revenue	\$ 7,468	\$ 490	\$ (490)	\$ -	\$ 7,468
Product royalty revenue	51,209	-	-	-	51,209
Product sales revenue	36,678	56,237	(18,038)	-	74,877
Co-promotion revenue	-	-	-	-	-
Contract and collaboration revenue	2,457	-	(829)	-	1,628
<b>Total revenues</b>	<b>97,812</b>	<b>56,727</b>	<b>(19,357)</b>	<b>-</b>	<b>135,182</b>
Costs and expenses:					
Costs of goods sold	18,656	17,639	(18,038)	-	18,257
Intangible assets amortization	-	-	-	17,081	17,081
Research and development expenses	22,285	14,698	(490)	-	36,493
General and administrative expenses	22,363	4,628	-	(1,221)	25,770
Selling and marketing expenses	1,617	1,768	(829)	-	2,556
<b>Total costs and expenses</b>	<b>64,921</b>	<b>38,733</b>	<b>(19,357)</b>	<b>15,860</b>	<b>100,157</b>
<b>Income from operations</b>	<b>32,891</b>	<b>17,994</b>	<b>-</b>	<b>(15,860)</b>	<b>35,025</b>
Non-operating income (expense):					
Interest income	155	18	-	-	173
Interest expense	(784)	-	-	(16,057)	(16,841)
Other non-operating income (expense), net	1,947	(175)	-	-	1,772
<b>Total other income</b>	<b>1,318</b>	<b>(157)</b>	<b>-</b>	<b>(16,057)</b>	<b>(14,896)</b>
<b>Income (loss) before income taxes</b>	<b>34,209</b>	<b>17,837</b>	<b>-</b>	<b>(31,917)</b>	<b>20,129</b>
Income tax provision	(10,989)	(5,572)	-	11,933	(4,628)
<b>Net income (loss)</b>	<b>\$ 23,220</b>	<b>\$ 12,265</b>	<b>\$ -</b>	<b>\$ (19,984)</b>	<b>\$ 15,501</b>

See accompanying Notes to unaudited pro forma combined consolidated financial information.

SUCAMPO PHARMACEUTICALS, INC.  
 UNAUDITED PRO FORMA COMBINED CONSOLIDATED BALANCE SHEET  
 AS OF SEPTEMBER 30, 2015  
 (in thousands, except share and per share data)

	Historical		Inter company Eliminations	Transaction Adjustments	Pro Forma Combined Consolidated
	As Of				
	September 30, 2015	September 30, 2015			
Sucampo	R-Tech Ueno (see Note 2)	(see Note 3)	(see Note 5)		
<b>Assets</b>					
<b>Current assets:</b>					
Cash and cash equivalents	\$ 91,505	\$ 58,811	\$ -	\$ (268,753) <sup>5a</sup> 250,000 <sup>5c</sup> (3,914) <sup>5d</sup> (16,091) <sup>5e</sup>	\$ 111,558
Investments, current	38,022	-	-	-	38,022
Product royalties receivable	19,328	-	-	-	19,328
Accounts receivable, net	6,682	12,121	-	(10,186) <sup>5b</sup>	8,617
Restricted cash, current	1,927	-	-	-	1,927
Inventory	296	15,014	-	22,549 <sup>5b</sup>	37,859
Prepaid expenses and other current assets	3,686	-	-	22,802 <sup>5b, 5e</sup>	26,488
<b>Total current assets</b>	<b>161,446</b>	<b>85,946</b>	<b>-</b>	<b>(3,593)</b>	<b>243,799</b>
Investments, non-current	5,124	49,166	-	(49,166) <sup>5b</sup>	5,124
Property and equipment, net	2,296	2,898	-	217 <sup>5b</sup>	5,411
Intangible assets, net	136	553	-	140,247 <sup>5b</sup>	140,936
Goodwill	-	-	-	61,228 <sup>5b</sup>	61,228
Deferred tax assets, net	3,136	-	-	-	3,136
Deferred charge, non-current	1,474	-	-	-	1,474
Other assets	160	444	-	5 <sup>5b</sup>	609
<b>Total assets</b>	<b>\$ 173,772</b>	<b>\$ 139,007</b>	<b>\$ -</b>	<b>\$ 148,938</b>	<b>\$ 461,717</b>
<b>Liabilities and Stockholders' Equity</b>					
<b>Current liabilities:</b>					
Accounts payable	\$ 4,936	\$ 2,379	\$ -	\$ 2,855 <sup>5b</sup>	\$ 10,170
Accrued expenses	10,151	678	-	(678) <sup>5b</sup>	10,151
Deferred revenue, current	1,152	-	(613)	(539) <sup>5b</sup>	-
Co-laboration obligation	5,552	-	-	-	5,552
Income tax payable	691	1,780	-	3,245 <sup>5b</sup>	5,716
Notes payable, current	8,411	-	-	18,750 <sup>5f</sup>	27,161
Deferred tax liability, current	-	-	-	-	-
Other current liabilities	2,581	4,635	-	(1,353) <sup>5b</sup>	5,863
<b>Total current liabilities</b>	<b>33,474</b>	<b>9,472</b>	<b>(613)</b>	<b>22,280</b>	<b>64,613</b>
Notes payable, non-current	13,330	8,713	-	222,537 <sup>5f</sup>	244,580
Deferred revenue, non-current	4,586	-	(3,566)	(1,020) <sup>5b</sup>	-
Deferred tax liability, non-current	210	14,980	-	47,947 <sup>5b</sup>	63,137
Other liabilities	4,384	589	-	8,758 <sup>5b</sup>	13,731
<b>Total liabilities</b>	<b>65,984</b>	<b>33,754</b>	<b>(4,179)</b>	<b>300,502</b>	<b>386,061</b>
<b>Stockholders' equity:</b>					
Preferred stock, \$0.01 par value; 5,000,000 shares authorized at September 30, 2015 and December 31, 2014; no shares issued and outstanding at September 30, 2015 and December 31, 2014	-	-	-	-	-
Class A common stock, \$0.01 par value; 270,000,000 shares authorized at September 30, 2015 and December 31, 2014; 45,312,051 and 44,602,988 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	453	5,558	-	(5,558) <sup>5g</sup>	453
Class B common stock, \$0.01 par value; 75,000,000 shares authorized at September 30, 2015 and December 31, 2014; no shares issued and outstanding at September 30, 2015 and December 31, 2014	-	-	-	-	-
Additional paid-in capital	95,749	5,059	-	(5,059) <sup>5g</sup>	95,749
Accumulated other comprehensive income	14,411	31,979	-	(31,979) <sup>5g</sup>	14,411
Treasury stock, at cost; 524,792 shares at September 30, 2015 and December 31, 2014	(2,313)	(4)	-	4 <sup>5g</sup>	(2,313)
Retained earnings	9,488	62,661	4,179	(108,972) <sup>5d, 5e</sup>	(32,644)
<b>Total stockholders' equity</b>	<b>117,788</b>	<b>105,253</b>	<b>4,179</b>	<b>(151,564)</b>	<b>75,656</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 173,772</b>	<b>\$ 139,007</b>	<b>\$ -</b>	<b>\$ 148,938</b>	<b>\$ 461,717</b>

See accompanying Notes to unaudited pro forma combined consolidated financial information.

### **Note 1 – Description of the Business Combination**

On October 20, 2015, Sucampo completed its acquisition of 10,262,903 shares and 318,400 stock acquisition rights of R-Tech pursuant to a previously announced tender offer in Japan (the “Tender Offer”), according to which Sucampo’s wholly owned Japanese subsidiary, Sucampo Pharma LLC (the “Purchaser”), offered to purchase all of the outstanding shares of R-Tech’s common stock (other than the shares acquired pursuant to the Purchase Agreement (as defined in the next sentence)). In addition, on October 20, 2015, the Registrant acquired 8,571,900 shares of R-Tech in accordance with the terms of the Share Purchase Agreement (“Purchase Agreement”) by and between Sucampo and the founders of R-Tech, who are also the founders of Sucampo, and a related entity. Following these acquisitions, Sucampo directly and indirectly owned approximately 98% of the outstanding shares of R-Tech; on December 8, 2015, the Purchaser acquired the remaining shares of R-Tech through a squeeze-out process under Japanese law.

R-Tech shareholders who tendered their shares in the tender offer or surrendered their shares in the squeeze-out process received ¥1,900, or \$15.77 in cash, for each issued and outstanding share of R-Tech common stock. Under the Purchase Agreement, the founders and their related entity received ¥1,400, or \$11.73, in cash for each such share.

### **Note 2 — Basis of Presentation**

The accompanying unaudited pro forma combined consolidated financial information was prepared in accordance with Article 11 of SEC Regulation S-X. The unaudited pro forma combined consolidated balance sheet was prepared using the historical balance sheets of Sucampo and R-Tech as of September 30, 2015 and assumes the proposed business combination occurred on September 30, 2015. R-Tech’s assets and liabilities have been measured at fair value as of October 20, 2015, which represents the date R-Tech was acquired by Sucampo. R-Tech’s fiscal year ends on March 31 and Sucampo’s fiscal year ends on December 31. The pro forma combined consolidated financial information has been prepared to conform R-Tech’s historical financial information to a year-end of December 31. The unaudited pro forma combined consolidated statements of operations were prepared using:

- the historical unaudited statement of operations of Sucampo for the nine months ended September 30, 2015;
- the historical audited statement of operations of Sucampo for the year ended December 31, 2014;
- the historical unaudited statement of income (loss) of R-Tech for the six months ended September 30, 2015;
- the historical unaudited statement of income (loss) of R-Tech for the three months ended March 31, 2015;
- the historical unaudited statement of income (loss) of R-Tech for the three months ended March 31, 2014; and
- the historical audited statement of income (loss) of R-Tech for the year ended March 31, 2015.

Sucampo’s historical audited and unaudited financial statements were prepared in accordance with U.S. GAAP and presented in thousands of U.S. dollars. R-Tech’s historical audited and unaudited financial statements were prepared in accordance with Japanese GAAP and presented in thousands of yen. The historical R-Tech financial statements included within the unaudited pro forma combined consolidated balance sheet and statements of operations have been adjusted to conform to Sucampo’s year end, and certain reclassifications were made to align R-Tech’s financial statement presentation with that of Sucampo. R-Tech’s historical audited and unaudited financial statements were reconciled to U.S. GAAP, and the Japanese GAAP to U.S. GAAP conversion adjustments have been applied to the historical R-Tech column as presented and discussed in the accompanying notes. A description of the adjustments to convert R-Tech from Japanese GAAP to U.S. GAAP is included in Note 17 to the historical audited financial statements of R-Tech for the years ended March 31, 2015, 2014 and 2013, filed as Exhibit 99.1 to the Form 8-K/A.

R-Tech’s historical audited and unaudited financial statements, Japanese GAAP to U.S. GAAP adjustments and pro forma adjustments were translated from yen to U.S. dollars using the period-end rate of \$0.0083 per yen for the unaudited pro forma combined consolidated balance sheet as of September 30, 2015 and the historical average rates during the nine months ended September 30, 2015 and the year ended December 31, 2014 of \$0.0083 and \$0.0095 per yen, respectively, for the unaudited pro forma combined consolidated statements of operations. The income statements and balance sheet of R-Tech have been adjusted to conform to the Sucampo periods presented, reclassified to align to Sucampo’s presentation, converted to U.S. GAAP and converted to U.S. dollars as follows:

Conforming schedules of historical statement of income (loss) of R-Tech for the year ended December 31, 2014 (in thousands):

	A	B	C	(A - B + C) = D	E	F	(D + E + F) = G	
	Historical R-Tech Uno							
	12 Months Ended March 31, 2015 (Japanese GAAP)	3 Months Ended March 31, 2015 (Japanese GAAP)	3 Months Ended March 31, 2014 (Japanese GAAP)	12 Months Ended December 31, 2014 (Japanese GAAP)	Reclassification Adjustments (Japanese GAAP)	US GAAP Adjustments	12 Months Ended December 31, 2014 (US GAAP)	12 Months Ended December 31, 2014 (US GAAP)
<b>Revenues:</b>								
Research and development revenue	¥ -	¥ -	¥ -	¥ -	¥ 59,800	¥ -	¥ 59,800	\$ 567
Product royalty revenue	100,000	25,000	25,000	100,000	(100,000)	-	-	-
Product sales revenue	6,459,429	2,364,834	1,337,859	5,482,454	40,200	54,948	5,527,602	52,374
Co-promotion revenue	-	-	-	-	-	-	-	-
Contract and collaboration revenue	-	-	-	-	-	-	-	-
<b>Total revenues</b>	<b>6,559,429</b>	<b>2,389,834</b>	<b>1,362,859</b>	<b>5,532,454</b>	<b>-</b>	<b>54,948</b>	<b>5,587,402</b>	<b>52,941</b>
<b>Costs and expenses:</b>								
Costs of goods sold	2,286,181	710,828	494,130	2,069,483	-	(43,026)	2,026,457	19,201
Intangible assets impairment	-	-	-	-	-	-	-	-
Research and development expenses	1,830,027	613,275	389,461	1,606,213	-	95,603	1,701,816	16,125
General and administrative expenses	584,846	150,978	126,195	560,063	53,107	(32,429)	580,741	5,503
Selling and marketing expenses	236,058	62,158	54,596	228,496	(39,855)	-	188,641	1,787
Depreciation, amortization	12,829	3,489	3,912	13,252	(13,252)	-	-	-
<b>Total costs and expenses</b>	<b>4,949,941</b>	<b>1,540,728</b>	<b>1,068,294</b>	<b>4,477,507</b>	<b>-</b>	<b>20,148</b>	<b>4,497,655</b>	<b>42,616</b>
<b>Income from operations</b>	<b>1,609,488</b>	<b>849,106</b>	<b>294,565</b>	<b>1,054,947</b>	<b>-</b>	<b>34,800</b>	<b>1,089,747</b>	<b>10,325</b>
<b>Non-operating income (expense):</b>								
Interest income	2,505	640	607	2,472	-	-	2,472	23
Interest expense	-	-	-	-	-	-	-	-
Foreign exchange translation gains (losses)	143,158	2,398	(22,273)	118,487	(118,487)	-	-	-
Fixed asset retirement loss	(87)	-	-	(87)	87	-	-	-
Other non-operating income (expense), net	8,029	(512)	24	8,565	118,400	(8,366)	118,599	1,124
<b>Total other income</b>	<b>153,605</b>	<b>2,526</b>	<b>(21,642)</b>	<b>129,437</b>	<b>-</b>	<b>(8,366)</b>	<b>121,071</b>	<b>1,147</b>
<b>Income (loss) before income taxes</b>	<b>1,763,093</b>	<b>851,632</b>	<b>272,923</b>	<b>1,184,383</b>	<b>-</b>	<b>26,434</b>	<b>1,210,817</b>	<b>11,472</b>
Income tax provision	(464,082)	(240,672)	(54,718)	(278,127)	-	34,452	(243,675)	(2,309)
<b>Net income (loss)</b>	<b>¥ 1,299,011</b>	<b>¥ 610,960</b>	<b>¥ 218,205</b>	<b>¥ 906,256</b>	<b>¥ -</b>	<b>¥ 60,886</b>	<b>¥ 967,142</b>	<b>\$ 9,163</b>

Conforming schedules of historical statement of income (loss) of R-Tech for the nine months ended September 30, 2015 (in thousands):

	A	B	(A + B) = C	D	E	(C + D + E) = F	
	Historical R-Tech Ueno						
	6 Months Ended September 30, 2015 (Japanese GAAP)	3 Months Ended March 31, 2015 (Japanese GAAP)	9 Months Ended September 30, 2015 (Japanese GAAP)	Reclassification Adjustments (Japanese GAAP)	US GAAP Adjustments	9 Months Ended September 30, 2015 (US GAAP)	9 Months Ended September 30, 2015 (US GAAP)
<b>Revenues:</b>							
Research and development revenue	¥ -	¥ -	¥ -	¥ 59,300	¥ -	¥ 59,300	\$ 490
Product royalty revenue	50,000	25,000	75,000	(75,000)	-	-	-
Product sales revenue	3,740,564	2,364,834	6,105,398	15,700	679,029	6,800,127	56,237
Co-promotion revenue	-	-	-	-	-	-	-
Contract and collaboration revenue	-	-	-	-	-	-	-
<b>Total revenues</b>	<b>3,790,564</b>	<b>2,389,834</b>	<b>6,180,398</b>	<b>-</b>	<b>679,029</b>	<b>6,859,427</b>	<b>56,727</b>
<b>Costs and expenses:</b>							
Costs of goods sold	1,456,386	710,828	2,167,214	-	(34,311)	2,132,903	17,639
Intangible assets impairment	-	-	-	-	-	-	-
Research and development expenses	997,131	613,275	1,610,406	-	166,884	1,777,290	14,698
General and administrative expenses	322,155	150,978	473,133	113,482	(26,978)	559,637	4,628
Selling and marketing expenses	253,984	62,158	316,142	(102,332)	-	213,810	1,768
Depreciation, amortization	7,661	3,489	11,150	(11,150)	-	-	-
<b>Total costs and expenses</b>	<b>3,037,317</b>	<b>1,540,728</b>	<b>4,578,045</b>	<b>-</b>	<b>105,596</b>	<b>4,683,640</b>	<b>38,733</b>
<b>Income from operations</b>	<b>753,247</b>	<b>849,106</b>	<b>1,602,353</b>	<b>-</b>	<b>573,434</b>	<b>2,175,787</b>	<b>17,994</b>
<b>Non-operating income (expense):</b>							
Interest income	1,594	640	2,234	-	-	2,234	18
Interest expense	-	-	-	-	-	-	-
Foreign exchange translation gains (losses)	(15,511)	2,398	(13,113)	13,113	-	-	-
Fixed asset retirement loss	(7,915)	-	(7,915)	7,915	-	-	-
Other non-operating income (expense), net	365	(512)	(147)	(21,028)	15	(21,160)	(175)
<b>Total other income</b>	<b>(21,467)</b>	<b>2,526</b>	<b>(18,941)</b>	<b>-</b>	<b>15</b>	<b>(18,926)</b>	<b>(157)</b>
<b>Income (loss) before income taxes</b>	<b>731,780</b>	<b>851,632</b>	<b>1,583,412</b>	<b>-</b>	<b>573,449</b>	<b>2,156,861</b>	<b>17,837</b>
Income tax provision	(179,266)	(240,672)	(419,938)	-	(253,845)	(673,783)	(5,572)
<b>Net income (loss)</b>	<b>¥ 552,514</b>	<b>¥ 610,960</b>	<b>¥ 1,163,474</b>	<b>¥ -</b>	<b>¥ 319,604</b>	<b>¥ 1,483,077</b>	<b>\$ 12,265</b>

Conforming schedules of historical balance sheet of R-Tech as of September 30, 2015 (in thousands, except share and per share data):

	A	B	C	(A + B + C) = D	
	<u>Historical R-Tech Ueno</u> As of September 30, 2015 (Japanese GAAP)	Reclassification Adjustments (Japanese GAAP)	US GAAP Adjustments	As of September 30, 2015 (US GAAP)	As of September 30, 2015 (US GAAP)
<b>Assets</b>					
Current assets:					
Cash and cash equivalents	¥ 7,085,672	¥ -	¥ -	¥ 7,085,672	\$ 58,811
Accounts receivable, net	948,850	538,707	(27,209)	1,460,348	12,121
Inventory	1,822,093	-	(13,145)	1,808,948	15,014
Prepaid expenses and other current assets	538,707	(538,707)	-	-	-
<b>Total current assets</b>	<b>10,395,322</b>	<b>-</b>	<b>(40,354)</b>	<b>10,354,968</b>	<b>85,946</b>
Investments, non-current	5,977,100	(53,484)	-	5,923,616	49,166
Property and equipment, net	324,773	-	24,391	349,164	2,898
Intangible assets, net	62,718	-	3,902	66,620	553
Other assets	-	53,484	-	53,484	444
<b>Total assets</b>	<b>¥ 16,759,913</b>	<b>¥ -</b>	<b>¥ (12,061)</b>	<b>¥ 16,747,852</b>	<b>\$ 139,007</b>
<b>Liabilities and Stockholders' Equity</b>					
Current liabilities:					
Accounts payable	¥ 286,606	¥ -	¥ -	¥ 286,606	\$ 2,379
Accrued expenses	11,617	-	70,014	81,631	678
Income tax payable	214,490	-	-	214,490	1,780
Other current liabilities	525,216	-	33,269	558,485	4,635
<b>Total current liabilities</b>	<b>1,037,929</b>	<b>-</b>	<b>103,283</b>	<b>1,141,212</b>	<b>9,472</b>
Long term debt	1,049,810	(1,049,810)	-	-	-
Notes payable, non-current	-	1,049,810	-	1,049,810	8,713
Deferred tax liability, non-current	1,749,657	-	55,104	1,804,761	14,980
Other liabilities	29,306	41,655	-	70,961	589
Asset retirement liabilities	41,655	(41,655)	-	-	-
<b>Total liabilities</b>	<b>3,908,357</b>	<b>-</b>	<b>158,387</b>	<b>4,066,744</b>	<b>33,754</b>
Stockholders' equity:					
Preferred stock, \$0.01 par value; 5,000,000 shares authorized at September 30, 2015 and December 31, 2014; no shares issued and outstanding at September 30, 2015 and December 31, 2014	-	-	-	-	-
Class A common stock, \$0.01 par value; 270,000,000 shares authorized at September 30, 2015 and December 31, 2014; 45,312,051 and 44,602,988 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	-	669,688	-	669,688	5,558
Class B common stock, \$0.01 par value; 75,000,000 shares authorized at September 30, 2015 and December 31, 2014; no shares issued and outstanding at September 30, 2015 and December 31, 2014	-	-	-	-	-
Additional paid-in capital	-	609,488	-	609,488	5,059
Accumulated other comprehensive income	-	4,078,427	(225,559)	3,852,868	31,979
Treasury stock	(495)	-	-	(495)	(4)
Retained earnings	7,494,448	-	55,111	7,549,559	62,661
Common stock - authorized 38,400,000 shares; issued, 19,322,500 shares; issued, 19,322,500 shares in 2015, 19,309,800 shares in 2014	669,688	(669,688)	-	-	-
Capital surplus	609,488	(609,488)	-	-	-
Unrealized gain on available-for-sale securities	3,977,419	(3,977,419)	-	-	-
Stock acquisition rights	101,008	(101,008)	-	-	-
<b>Total stockholders' equity</b>	<b>12,851,556</b>	<b>-</b>	<b>(170,448)</b>	<b>12,681,108</b>	<b>105,253</b>
<b>Total liabilities and stockholders' equity</b>	<b>¥ 16,759,913</b>	<b>¥ -</b>	<b>¥ (12,061)</b>	<b>¥ 16,747,852</b>	<b>\$ 139,007</b>

The business combination of Sucampo and R-Tech has been accounted for using the acquisition method of accounting under the provisions of ASC 805, with Sucampo representing the accounting acquirer. Accordingly, the historical financial statements have been adjusted to give effect to the impact of the consideration paid in connection with the business combination. In the unaudited pro forma combined consolidated balance sheet, Sucampo's cost to acquire R-Tech has been allocated to the assets acquired and liabilities assumed based upon management's preliminary estimate of what their respective fair values would be as of the date of the business combination. The pro forma adjustments are preliminary and are based upon available information and certain assumptions which management believes are reasonable under the circumstances and which are described herein. Actual results may differ materially from the assumptions within the accompanying unaudited pro forma combined consolidated financial information. Under ASC 805, generally all assets acquired and liabilities assumed are recorded at their acquisition date fair value. For purposes of the pro forma information presented herein, the fair value of R-Tech's identifiable tangible and intangible assets acquired and liabilities assumed are based on a preliminary estimate of fair value. Any excess of the purchase price over the fair value of identified tangible and intangible assets acquired and liabilities assumed will be recognized as goodwill. Management believes the estimated fair values utilized for the assets to be acquired and liabilities assumed are based on reasonable estimates and assumptions. Preliminary fair value estimates may change as additional information becomes available and such changes could be material, as certain valuations and other studies have yet to progress to a stage where there is sufficient information for definitive measurement.

The unaudited pro forma combined consolidated statements of operations also include certain purchase accounting adjustments, including items expected to have a continuing impact on the combined results, such as increased amortization expense on acquired intangible assets. The unaudited pro forma combined consolidated statements of operations do not include the impacts of any revenue, cost or other operating synergies that may result from the business combination or any related restructuring costs that may be contemplated. Sucampo and R-Tech have begun collecting information in order to formulate detailed integration plans to deliver planned synergies. However, at this time, the status of the integration plans is too uncertain to include in the pro forma financial statements.

#### Financing Arrangement

On October 16, 2015, Sucampo entered into a credit facility that provides for term loans in the aggregate principal amount of \$250.0 million (the "Term Loans") and allows for the incurrence of incremental loans in an amount up to \$25.0 million. The Term Loans bear interest, at Sucampo's option, at either the Adjusted Eurodollar Rate (as defined in the credit facility) plus 7.25% or the Adjusted Base Rate (as defined in the credit facility) plus 6.25%. The Adjusted Eurodollar Rate is subject to a 1.00% floor and the Adjusted Base Rate is subject to a 2.00% floor. The proceeds of the Term Loans were used to finance a portion of the cash consideration of the purchase price in exchange for R-Tech ordinary shares. Upon closing of the acquisition, outstanding borrowings under the Term Loan were approximately \$250.0 million.

#### **Note 3 – Intercompany Eliminations**

Intercompany elimination adjustments represent the elimination of existing balances included within the balance sheets and statements of operations of Sucampo and R-Tech, which at the close of the acquisition were considered intercompany transactions, including:

- R-Tech product sales revenue recorded as cost of goods sold by Sucampo.
- R-Tech research and development revenue recorded as research and development expenses by Sucampo.
- Sucampo contract and collaboration revenue recorded as selling and marketing expenses by R-Tech.
- Sucampo deferred revenue resulting from the deferral of upfront payments relating to the exclusive supply agreements with R-Tech.
- Accounts payable between Sucampo and R-Tech.

#### **Note 4 — Purchase Price**

The total purchase consideration to acquire the shares and options of R-Tech was \$275.1 million. Under the terms of the tender offer, R-Tech shareholders were entitled to receive ¥1,900, or \$15.77, in cash for each issued and outstanding R-Tech ordinary share. Under the Purchase Agreement, the founders and their related entity received ¥1,400, or \$11.73, in cash for each such share. Following these acquisitions, Sucampo directly and indirectly owned approximately 98% of the outstanding shares of R-Tech. The Company acquired the remaining shares of R-Tech through a squeeze-out process under Japanese law on December 8, 2015 at a price of 1,900 JPY per share.

For the purpose of preparing the accompanying unaudited pro forma combined consolidated balance sheet as of September 30, 2015, the purchase price was calculated as follows (amounts in thousands, except share data):

Offering price per share of R-Tech in tender offer and squeeze-out	¥	1,900
Average Japanese Yen to U.S. Dollar exchange rate at October 20, 2015 and December 8, 2015 for the tender and squeeze out shares, respectively		120.48
Price per share acquired via tender offer and squeeze-out, in dollars	\$	15.77
Outstanding shares acquired via tender offer and squeeze-out		11,069
Consideration paid pursuant to tender offer and squeeze-out	\$	174,584
Offering price per share of R-Tech in purchase agreement	¥	1,400
Japanese Yen to U.S. Dollar exchange rate at October 20, 2015		119.35
Price per share acquired via purchase agreement, in dollars	\$	11.73
Outstanding shares acquired via purchase agreement		8,572
Consideration paid pursuant to purchase agreement	\$	100,533
Total purchase consideration	\$	275,117

The following is a summary of the preliminary allocation of the above purchase price as reflected in the unaudited pro forma combined consolidated balance sheet as of September 30, 2015 (amounts in thousands):

(In thousands)	As of October 20, 2015
Cash	\$ 62,097
Accounts receivable	8,299
Inventory	37,563
Prepaid expense	3,425
Property, plant and equipment	3,115
Other long term assets	449
Accounts payable and accrued liabilities	(11,598)
Income tax payable	(5,025)
Other liabilities, current	(3,282)
Deferred tax liability, net	(62,927)
Other liabilities, long term	(9,347)
R-Tech shares of Sucampo stock (treasury stock)	43,956
Total fair value of tangible assets acquired and liabilities assumed	66,725
Acquired in-process research and development	6,200
Acquired intangible assets	134,600
Goodwill	61,228
Total purchase price	<u>\$ 268,753</u>
Total purchase price	\$ 268,753
Settlement of net receivable from pre-existing relationship	6,364
Total consideration	<u>\$ 275,117</u>

The goodwill balance is primarily attributed to the assembled workforce, expanded market opportunities and cost and other operating synergies anticipated upon the integration of the operations of Sucampo and R-Tech.



## **Note 5 – Unaudited Pro Forma Combined Consolidated Balance Sheet Adjustments**

### *Purchase Accounting Adjustments:*

- (a) Reflects \$268.8 million, which represents the cash purchase price paid to R-Tech common shareholders as calculated in Note 4.
- (b) Reflects the change in book value for R-Tech's asset and liability balances to reflect estimated fair value as of the acquisition date, October 20, 2015.
- (c) Reflects an adjustment of \$250.0 million to record the proceeds from the issuance of debt to finance the acquisition.
- (d) Reflects transaction costs attributable to the transaction.
- (e) Reflects debt issuance costs related to the new debt.
- (f) Reflects the current and long term portions of the new debt.
- (g) Reflects adjustments to eliminate R-Tech's historical shareholders' equity, which represents the historical book value of R-Tech's net assets, as a result of the application of purchase accounting.

## **Note 6 – Unaudited Pro Forma Combined Consolidated Statements of Operations Adjustments**

### *Purchase Accounting Adjustments:*

- (a) Reflects adjustments for the year ended December 31, 2014 and the nine months ended September 30, 2015 for amortization expense related to the fair value of identified intangible assets with definite lives.
- (b) Reflects the removal of transaction costs related to the acquisition for the nine months ended September 30, 2015.
- (c) Reflects the adjustments to interest expense and amortization of debt issuance costs resulting from the new debt.
- (d) Reflects adjustments to income tax expense for the year ended December 31, 2014 and nine months ended September 30, 2015, for the tax effect of the transaction adjustments. Because the tax rate used for these pro forma financial statements is the statutory rate and an estimate, it will likely vary from the effective rate in periods subsequent to the completion of the business combination, and those differences may be material.